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CHAPTER I 
 
INTRODUCTION 
 
Antibiotic History 
 In 1929 Alexander Fleming changed the future of medicine and how we treat 
disease.1 The publication of the antibacterial effect of the fungus Penicillium upon the 
growth of Bacillus influenzae (since renamed Haemophilus influenzae) began the battle 
between man and microbe (Figure 1).  The discovery and subsequent introduction of 
penicillin into the clinic not only opened a new field of research, but also an entirely new 
industry.2 Penicillin G was approved by the FDA in 1943 and an explosion of discovery 
soon followed.3 Soon after the successful introduction of penicillin, several antibiotics 
were introduced to the clinic in the following 25 years.  This golden age of antibiotics 
was responsible for the introduction of streptomycin, tetracycline, methicillin, 
fosfomycin, and more. 
 After this explosion of new drugs hit the market, it took another thirty-two years 
for another new class of antibiotic to be introduced into the clinic (Figure 2).4,5 The time 
elapsed between the introduction of trimethoprim in 1968 and the oxazolidinones in 2000 
was filled with many factors that influenced the future of drug discovery and antibiotic 
drug discovery in particular.  During this time many large pharmaceutical companies 
began to merge and focus on targets that would require patients to take medications over 
a longer period of time.  Larger companies needed larger profits in order to remain stable.  
With the flood of antibacterial agents that hit the market in the 1950’s and 1960’s, market 
competition was fierce and research turned to new areas with higher profit potential.6 
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Figure 1: A) Alexander Fleming in his lab. Inset: a microplate of the fungus Penicillium 
inhibiting the growth of E. coli.  B) Sign placard demonstrating one of the less serious, 
but no less meaningful, changes made in the medical establishment. 
 
 
 
 
 
 
Figure 2: Cartoon timeline of antibiotic introduction to the clinic.  Modified from 
Reference #5. 
 
 
A. B. 
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 There has been a re-focusing of research into novel antibacterial agents in recent 
years.  The last eight years has seen new classes of antibiotics hitting the markets, in the 
form of the oxazolidinones and lipopeptides.  The discovery of a new class of antibiotic 
that has yet to be introduced into the clinic, platensimycin, has also been reported.7 Much 
of this new research has been spurred by the increase in the number of antibiotic resistant 
infections being seen in the clinic.  Every antibiotic introduced into the clinic has had 
resistance reported shortly thereafter.  Antibiotic resistance was one of the factors that 
propagated the exit of many large companies from the antibiotic research field.  
However, in recent years, many smaller research firms have begun to take up the task of 
developing new antibiotics.3,4,8 
 
Antibiotic Resistance 
 In 2002, the global antibiotic market value was an estimated US $25 billion and 
estimated to be about the same in 2005 (Figure 3).  The top antibiotics totaled over US 
$8.5 billion in sales in the United States alone in 2005.9,10 While they remain profitable, 
antibiotics are less so when compared to other drugs, such as cholesterol controlling 
drugs where a single drug may make in excess of US $9 billion alone.2 Resistance also 
takes a major financial toll, costing an estimated US $5-20 billion a year.11 Therefore, 
despite its remaining profitability and overall sales increasing yearly, the number of new 
drugs hitting the market is falling rapidly (Figure 4).8 
 One of the main reasons for the increase in resistance seen over the last several 
years is that the cellular targets of antibiotics remain rather limited.  Antibiotics target  
 4 
Figure 3: Sales of antibiotics from the years 1996 to 2008.  Modified from Reference #8. 
 
 
 
Figure 4: Number of new antibiotics on the market from 1983 to 2007.  Modified from 
Reference #8. 
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 only a few main cellular functions: cell wall biosynthesis, protein synthesis, nucleic acid 
synthesis, folate metabolism, isoprenoid biosynthesis, and cell membrane structure 
disruption. The actual number of targets is fewer still as companies look for the greatest 
reward with the fewest number of side effects.  The few number of targets limits the 
search to those that either do not have human analogs or can be sufficiently discerned 
from their human analogs with adequate specificity. 
 Another reason for the increase in resistance is that there are several mechanisms 
by which a bacterium can become resistant to an antibiotic (Figure 5).  In addition, once a 
bacterium has developed a mechanism of resistance it can be easily transferred to other 
bacterium.  Resistance determinants can develop via mutation of genomically encoded 
enzymes or be taken up from the environment or via horizontal gene transfer between 
bacteria (Figure 6).  This allows resistance determinants to quickly spread through 
bacterial populations and compounds problems combating antibiotic resistance.12 In fact, 
it has been recently shown that antibiotic resistant determinants can be found in soil 
microbes from many different environments and that some bacteria are able to use 
current antibiotics as the sole carbon source in their diet.13-15 
 In the face of these odds it is imperative that the development of new antibiotics 
and maintaining the effectiveness of current antibiotics become a priority.16 One method 
of looking for new drugs is to find new targets.  In 2006, Payne, et al. from 
GlaxoSmithKline (GSK) published an interesting paper in which they made systematic 
mutations throughout the Streptococcus pneumoniae to determine which genes were 
essential for the growth and development of the bacterium.  They found that 127 of the 
358 genes tested were essential.  These essential genes were a good starting point to 
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Figure 5: Cartoon depiction of the five methods of bacterial resistance to antibiotics. 
Modified from Reference #13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6: Cartoon depicting the many ways transposable resistance elements can be 
transferred among bacterial populations. Modified from Reference #13. 
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 7 
begin high-throughput screening campaigns for targeted enzymes as well as whole cell 
assays.  This is just one example of a strategy to develop new antimicrobial compounds.17 
 Other strategies for combating antibiotic resistance are plentiful.  These include 
but are not limited to: finding new compounds for already established targets, such as 
MurA in cell wall biosynthesis,18 finding compounds to target new enzymes, such as 
platensimycin inhibition of FabF in bacterial type II fatty-acid synthesis,7 inhibiting 
antibiotic resistance propagation,19 cell-division inhibition,20 inhibiting mechanisms 
involved with persistence and adaptation,21 efflux-pump inhibitors,22 and stress response 
inhibitors.23 Many of these methods are promising and will probably lead to new 
antibiotics in the near future. 
 Until these new compounds can be clinically verified and reach the market, work 
is needed to maintain the effectiveness of current antibiotics.  One commercially effective 
solution has been to find a way to inhibit enzymatic mechanisms of resistance so the 
antibiotic can perform its intended function.  The β-lactamase inhibitors clavulanate, 
tazobactam, and sulbactam have been used clinically for decades to maintain the utility of 
β-lactam drugs, like amoxicillin.24 Clavulanate was first discovered in 1972 and went on 
to be a commercial success, sold as a combination oral drug with amoxicillin as 
Augmentin (GSK)(Figure 7).25 It is possible that this method could be effective in  
 
 
 
 
 
 
 
Figure 7: Molecular structures of the components of Augmentin. 
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preserving the activity of many antibiotics where enzymatically catalyzed resistance is a 
key factor.  This method may also be a successful way to reintroduce old antibiotics into 
the clinic. 
 
Fosfomycin 
 One old antibiotic that may be resuscitated is the broad-spectrum antibiotic 
fosfomycin, 1.  Fosfomycin was first discovered by scientists at Merck as an isolate from 
certain species of Streptomyces.26 Its initial structure was determined by comparison to 
the synthetic compound.27 Fosfomycin was found to be a low molecular weight acid with 
a good ED50 to several various strains of infectious bacteria, including Escherichia coli, 
Klebsiella pneumoniae, Pseudomonas aeruginosa, and Staphylococcus aureus, marking 
it as an effective broad-spectrum antibiotic. 
 
 
 
 It was discovered that fosfomycin acts as a suicide inhibitor of the enzyme UDP-
N-acetylglucosamine enolpyruvoyl transferase (MurA) in both Gram-positive and Gram-
negative bacteria.  MurA catalyzes the first committed step in bacterial cell wall 
biosynthesis.  Fosfomycin inhibits this enzyme by forming a covalent adduct at the C-2 
position to a catalytically required active site cysteine, C115 (E. coli numbering)(Figure 
8).28,29 Also of note, the substrate UDP-N-acetylglucosamine (UDP-GlcNAc) is 
necessary for fosfomycin to inhibit MurA.  It is believed that this is due to UDP-GlcNAc 
causing a large conformational change in the enzyme opening C115 to attack. 
O
P
-O
-O
O
1 
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Figure 8: Crystal structure of MurA with fosfomycin covalently adducted to C115.  Also 
shown is UDP-GlcNAc, required to implement the structural rearrangement that exposes 
C115.  Made using PDB 1UAE. 
 
 Bacterial resistance to fosfomycin was noted early on via mutations in the uptake 
pathways necessary for the drug to enter the cells.28 Fosfomycin enters the bacterium via 
either the glycerophosphate (glpT) or hexose phosphate transport systems (uhp).  The 
glpT transport system is the primary system of flux for the antibiotic with the uhp system 
only becoming active in the presence of an inducer, such as glucose-6-phosphate.  
Bacteria that develop mutations in these uptake pathways are resistant to fosfomycin 
since the antibiotic cannot reach its target in the cytoplasm of the cell.  Resistance has 
also been reported via an altered target enzyme.  This enzyme, in M. tuberculosis, has a 
C114D mutation that allows the enzyme to remain active while also becoming resistant to 
fosfomycin.30 
C115 
Fos 
UDP-GlcNAc 
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 Another main source of bacterial resistance to fosfomycin is enzymatic in nature.  
Enzymatic fosfomycin resistance was first isolated from a multi-drug resistant plasmid, 
pOU900, isolated from a clinical infection of Serratia marcescens.31 The fosfomycin 
resistance determinant was isolated and named Tn2921.  It was later found that this 
determinant does not affect transport of fosfomycin into the cells, but was a novel 
enzymatic entity that modifies the antibiotic via the addition of the tri-peptide glutathione 
(GSH)(Figure 9).32-36 This enzyme is a metalloenzyme that requires Mn2+ for activity and 
is activated 100-fold by the presence of K+.37,38 
 Interestingly, the final product of the Tn2921 enzyme, FosA, is a covalent adduct 
of fosfomycin and GSH with the covalent bond formed at the C-1 position of 
fosfomycin.39 The crystal structure of the related, genomically encoded, FosA from 
Pseudomonas aeruginosa (60% sequence identity to the plasmid encoded, Tn2921 FosA) 
gave insight into the mechanism by which this reaction occurs.40 Fosfomycin coordinates 
directly to the Mn2+ ion at both the phosphonate moiety and the oxirane oxygen.  The K+ 
is not directly involved in catalysis, but it is 4.4 Å from the nearest phosphonate oxygen, 
so it may help orient fosfomycin in the active site for attack at the C-1 position.   
 Over the last several years BLAST searches against protein data banks have 
revealed several more genomically encoded FosA enzymes as well as two other classes 
of fosfomycin resistance enzyme, the FosB and FosX classes (Figure 10).  The FosB 
enzymes have about 30% sequence identity to the FosA enzymes but have slightly 
different function.41 The FosB enzymes are found in Gram-positive bacteria, which do 
not biosynthesize glutathione.  As such they may utilize either free L-cysteine or the 
newly described bacillathiol as a thiol substrate, Figure 9.42 The FosB enzymes are not 
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Figure 9: Mechanism of the FosA, FosB, and FosX enzymes. 
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Figure 10: Phylogram of the Fosfomycin Resistance Enzymes.  The FosA enzymes are 
in black, the FosB enzymes are in blue, and the FosX enzymes are in red. 
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activated by monovalent cations, but do retain the necessity of a divalent metal cation, 
most often Mg2+ is preferred.  No structure has been elucidated for these enzymes, but 
they are expected to be very similar to FosA based on sequence identity. 
 The FosX enzymes are a rather different class of Fos.  These enzymes also require 
a divalent metal cation; often Mn2+ is preferred, although Cu2+ can also work in many 
cases and is preferred in at least one.  These enzymes are also not activated by 
monovalent cations, similar to the FosB enzymes.  The major difference in these enzymes 
is that they do not use a thiol substrate for addition to the antibiotic but add water to the 
C-1 position of fosfomycin, hydrolyzing it to a 1,2-vicinal diol (Figure 9).43,44 There is 
also a broad range of activity within this class of enzyme in that some transfer exemplary 
resistance to E. coli when introduced on a plasmid vector, and some transfer almost no 
resistance at all.  This class of enzymes, therefore, may give deeper insights into the 
nature of enzyme structure/function relationships and offer a unique opportunity to study 
how these enzymes may have evolved. 
 
Enzyme Evolution 
 In 1999 O’Brien and Herschlag wrote a review detailing the myriad ways in 
which enzymes that were catalytically promiscuous could be easily used in adaptive 
evolution for the formation of new enzymes with new primary functions.45 The Fos 
enzymes provide an intriguing possibility to study the mechanism by which this may 
occur.  The primary example for this is the FosX enzyme from Mesorhizobium loti. 
 The M. loti FosX is a very poor resistance enzyme with a kcat = 0.15 s-1 and a 
minimum inhibitory constant (MIC) when transformed into E. coli on a plasmid vector of  
 14 
 
Figure 11: Development of new enzyme activities.  An evolved enzyme, for phosphonate 
metabolism for instance, can be developed from a promiscuous progenitor or from the 
mutation of another genetically determined enzyme following a gene duplication event.  
These evolved enzymes are incorporated into the genetic material of the bacterium, or 
they can be further mutated to become a promiscuous progenitor for other metabolic 
functions, like fosfomycin resistance.  This could also happen in reverse, which is why 
the circular depiction above is used. 
 
< 50 µg/mL on fosfomycin/LB-agar plates (compared to a kcat = 180 s-1 and MIC > 20 
mg/mL for the FosA from P. aeruginosa).  The M. loti FosX can, unlike any other Fos 
enzyme studied to date, catalyze both the FosX and FosA reactions, though both poorly. 
This leads one to wonder if this enzyme is truly a fosfomycin resistance enzyme, which it 
is most likely not. 
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 The M. loti FosX is located in the phn operon, an operon containing several genes 
responsible for the metabolism of phosphonate compounds (Figure 12).  Not much is 
known about this operon or the functions of the various genes of which it is composed.  It 
is for that reason that the actual function of the M. loti FosX is not known, but it is 
doubtful that it is primarily a resistance mechanism.  It is possible, however, that this 
enzyme may be an evolutionary precursor to both the actual FosA and FosX enzymes.  
The FosA enzyme is a GSH transferase, but it is structurally and mechanistically different 
from any of the canonical cytosolic GSH-transferases.  It has been previously posited that 
FosA may actually have evolved from a member of the Vicinal Oxygen Chelate (VOC) 
Superfamily, of which it is a member along with the extradiol dioxygenases, glyoxalase I, 
and others.46 It is possible that its more direct evolutionary precursor is something like 
the M. loti FosX, however, and that the FosX in turn evolved from another VOC family 
member. 
Figure 12: phn operon in M. loti 
 
 Much work has been done in recent years on trying to predict the future evolution 
of antibiotic resistance and also using what we do know about the evolution of related 
enzymes to create new functionality.11,47,48 A thorough understanding of the evolution of 
the Fos enzymes may aid in the future prediction of how resistance to this antibiotic 
might spread and become a model system for the study of other resistant mechanisms.  
Many of the tools devised over the last several years in protein engineering will also be of 
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aid in exploring how the Fos enzymes might have evolved from a catalytically 
promiscuous, although not very active, precursor. 
 
Drug Discovery 
 Many drug discovery efforts begin in one of three places – substrate analogs 
(often a result of rational screening), natural products, or high-throughput screening 
(HTS).  Early attempts at finding inhibitors for the FosA enzymes focused on the first of 
these three.  Several small phosphonates were screened for inhibitory capacity and one, 
phosphonoformate, proved to be an excellent transition-state analog inhibitor (Figure 
13).49 Phosphonoformate was not a specific inhibitor, however, as it showed toxicity to E. 
coli in an in vitro LB/agar plate assay.  No other small phosphonates were found to be 
good enough inhibitors to pursue further. 
 There have been published examples of inhibitors found for the MurA enzyme 
which look nothing like fosfomycin.18 One of the most effective ways to explore new 
chemical space for drug discovery is high-throughput screening (HTS).  HTS works on a 
principle of creating assays so that each well of a 96-, 384-, or 1536-well plate acts as a 
micro test tube (Figure 14).  These microplates enable one to run parallel assays to test 
several hundred to several thousand compounds at one time and quickly.  HTS assays 
typically involve using either purified enzymes or whole cells and are capable of being 
run using minimum steps and time.  An HTS assay typically can screen somewhere 
between 10,000 and 100,000 compounds a day and compound libraries can be anywhere 
from tens of thousands to millions of compounds.50,51 
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Figure 13: Phosphonoformate inhibits FosA by binding in the active site in the same 
place as fosfomycin.  The Pf molecule is shown in stick form above with the fosfomycin 
shown in wire form in an overlay of two different Pa1129 FosA structures.  Figure made 
using PDB 1LQP (fosfomycin) and 1NKI (phosphonoformate).  References #42 and 51. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 14: HTS theory – miniaturizing test tube experiments to run massively parallel 
reactions 
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  HTS assays are primarily an exercise in probability and statistics.  Given a large 
enough and diverse enough library, it becomes sufficiently probable that compounds of 
desired activity will be found.  Statistically, a hit is defined as a compound that gives a 
signal greater than three standard deviations above the mean signal, a 99% confidence 
interval.  HTS screens also need to be validated, automated, and reproducible.52 
Screening is only a first step in the larger process of drug discovery, but it can be an 
important way to find new chemical space to explore in the development of potent 
inhibitors of the fosfomycin resistance enzymes. 
 
This Work 
 Fosfomycin is underutilized in the USA despite its broad spectrum activity.  A 
recent meta-analysis of published clinical studies reported that fosfomycin was able to 
cure a number of infections in about 81% of cases, with improvement noted in another 
3% of patients.53 Still, despite the obvious health benefits of fosfomycin, it remains 
largely unused due to the nature of the antibiotic resistance mounted against it. 
 The work presented here attacks the problem of fosfomycin resistance from three 
fronts – uncovering the final mystery of how the substrate glutathione binds in the active 
site, exploring how these enzymes may have evolved, and developing HTS assays for the 
discovery of novel inhibitors that could provide therapeutic benefit. 
 The FosA and FosX enzymes have been mostly characterized in regards to their 
structure and function.  The final piece to the puzzle was the nature of GSH binding to 
FosA.  Due to the way that the enzyme packs in a crystal lattice, it is not possible to get 
crystals of FosA with GSH present.  Crystals do not form in the presence of GSH and 
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soaking experiments break up the crystals.  In order to solve this final piece of the puzzle, 
GSH was modeled into the active site of the FosA enzyme.  Subsequent mutagenesis 
studies of the putative binding residues helped to confirm the model (and agreed with 
another published study which identified potential GSH binding residues).54,55 This work 
helped to better characterize the nature of the structure/function relationships for FosA.   
 The final mechanistic work on FosA was also a valuable piece of knowledge in 
beginning to explore the evolution of the FosA enzymes from the catalytically 
promiscuous M. loti FosX.  The primary differences between the two enzymes were 
identified and multiple point mutations were made in an attempt to increase FosA activity 
and to introduce GSH binding and K+ activation.  Similar transformations have been done 
by making point mutations and replacing movable loops in other enzyme families.47 
Attempts to do this resulted in enzymes with decreased function, so a new course was 
selected. 
 DNA shuffling techniques have existed for several years and can be used to create 
genes of mixed origin and new function.48 Attempts to shuffle the DNA between the P. 
aeruginosa FosA and M. loti FosX have yielded some interesting results.  The mutation 
of three amino acids in the M. loti FosX effectively kills the enzymes’ FosX activity and 
greatly increases its FosA activity (from kcat = 0.001 s-1 to 1.5 s-1).57 The DNA shuffling 
mutants, which are 90% identical to M. loti FosX on the DNA level, have these mutations 
as well as the wholesale incorporation of the FosA K+-binding loop, as well as some 
other point mutations of unknown function.56 These are the results of initial attempts, and 
may be the result of contaminated samples, but they do offer good insight into the small 
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number of changes that may need to be made to evolve an active FosA from a relatively 
inactive FosX. 
 The final project outlined here is a broad attempt to find new inhibitors and new 
chemical space to explore in the search for inhibitors to the Fos class of enzymes.  The 
successful development of a FosA assay for the purified P. aeruginosa FosA should one-
day aid in the development of potent inhibitors to this enzyme.  The assay uses the thiol-
specific fluorophore monobromobimane (mBBr) to screen for the presence of residual 
substrate glutathione.  The whole assay takes only 1 hour to run to completion and is an 
extremely sensitive and effective assay.  Validation runs on a small number of 
compounds, 4800 from the Vanderbilt Collection, have resulted in six verified hits, one 
that is a sub-micromolar inhibitor.  Needless to say, the success of this assay in finding 
novel chemical entities in such a small number of compounds bodes well for the future 
screening of much larger compound libraries. 
 Also detailed here is the modification and development of a whole cell E. coli 
assay to test the bioactivity of compounds identified from the FosA HTS assay.  This 
assay uses a slightly modified version of the one published by Sarker et al.57 The 
bacterial growth indicator dye resazurin is reduced by live bacteria to resofurin.  This 
change introduces not only a change in color, from dark blue to pink/red, but also a 
marked change in fluorescence.  The ability to test for the bioactivity of inhibitors is key 
to the development of therapeutic agents.  Developing strong enzymatic inhibitors that 
cannot cross the cell membrane and reach its target is useless and must be mitigated.  
Bioactivity assays will also enable the ability to test for the specificity of inhibition.  One 
of the main problems with phosphonoformate was that it was not a specific inhibitor and 
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resulted in decreased growth in cells not stressed by antibiotic.49 This assay will help 
tailor inhibitors to be bioactive, but specific as well. 
 The FosA HTS assay should be directly translatable to the FosB enzymes.  The 
FosX enzymes, however, are a different story.  Several attempts were made to develop a 
separate purified enzyme assay for the FosX enzymes, using purified FosX from Listeria 
monocytogenes, a potent resistance enzyme.  All attempts to date have failed to develop a 
purified enzyme assay.  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Materials 
 
 FosA from Pseudomonas aeruginosa and FosX from both Listeria 
monocytogenes and Mesorhizobium loti, were purified as previously described.58 MnCl2 
and phosphonoformate were obtained from Alfa Aesar (Ward Hill, MA).  KCl, potassium 
phosphate (monobasic), ethylene diamine tetraacetic acid (EDTA), 
tris(hydroxymethyl)aminomethane (Tris), N-(2-hydroxyethyl)piperazine N’-(2-
ethanesulfonic acid) free acid (HEPES), 3-(N-morpholino)-propanesulfonic acid 
(MOPS), tetramethylammonium hydroxide (TMA-OH), Luria broth (LB), fosfomycin 
(MP Biomedical, Solon, OH), resazurin (Acros Organics, Geel, Belgium), Acetonitrile 
(HPLC grade), and dimethyl sulfoxide (DMSO) were obtained from Fisher (Waltham, 
MA).  Glutathione (reduced), isopropyl-β-D-thiogalactopyranoside (IPTG), dithiothreitol 
(DTT), and ampicillin were obtained from RPI (Mount Prospect, IL).  
Monobromobimane and thiazolyl blue tetrazolium bromide (MP Biomedical) were 
obtained from Sigma (St. Louis, MO).  AccQ-Fluor Derivatizing Reagent (AQC) was 
purchased from Waters (Milford, MA).  BL21 Gold (DE3) Competent Escherichia coli 
(Novagen – Madison, WI) and all restriction enzymes (New England Biolabs – Beverly, 
MA) were purchased from the Vanderbilt Molecular Biology Core (Nashville, TN).  96-
well microplates (Whatman, Florham Park, NJ) and 384 well microplates (Greiner Bio-
One, Monroe, NC) were obtained from VWR (West Chester, PA). Hydroxyapatite and 
Chelex 100 (Na+) were obtained from Bio-Rad (Hercules, CA).  DEAE Fast Flow resin 
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and the MonoQ 4.6/100 PE FPLC column were obtained from GE Healthcare and the 
Sephacryl S100 gel filtration column was from Pharmacia (now part of GE Healthcare, 
Piscataway, NJ)..  Silicon oil, Al's Oil, and microbatch crystallography trays were 
obtained from Hampton Research (Aliso Viejo, CA). 
 
Methods 
GSH Docking and Energy Minimization   
 The manual docking and energy minimization of GSH in the active site of FosA 
was performed by Rachel Rigsby and Eric Dawson and is detailed in Rigsby et al.55 
 
Generation of GSH Binding Mutants 
Site-directed mutagenesis was performed on the P. aeruginosa FosA expression 
plasmid using the QuikChange site-directed mutagenesis kit (Stratagene, La Jolla, CA).   
Oligonucleotide primers (Invitrogen, Carlsbad, CA) were designed to change codon 34 
from TGG to GCG (W34A) and CAC (W34H), codon 36 from CAG to AAC (Q36N), 
codon 39 from TAT to TTT (Y39F), codon 90 from AAG to GCG (K90A), codon 93 
from CGC to GCG (R93A), and to insert CGC GTC GAG (RVE) between codons 93 (R) 
and 94 (S).  All mutations were confirmed by DNA sequencing (Vanderbilt DNA 
Sequencing Core). 
 
Expression and Purification of GSH Binding Mutants 
Mutants were expressed and purified as described for native protein.58 Briefly, for 
the mutants of P. aeruginosa FosA, bacteria were lysed by sonication on ice followed by 
centrifugation to pellet the cell debris.  The lysate was dialyzed against 20 mM Tris (pH 
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7.5) with 1 mM DTT prior to loading onto a 2.8 x 18 cm DEAE-cellulose column 
equilibrated with the same buffer.  Protein was eluted with a salt gradient [(20 to 500 mM 
NaCl in 20 mM Tris (pH 7.5)] at 4 °C.  Fractions containing the enzyme were pooled and 
dialyzed against 20 mM KH2PO4 (pH 6.8) with 1 mM DTT.  Protein was passed 
isocratically through a 2.8 x 6.5 cm hydroxyapatite column equilibrated with the same 
buffer.  Fractions containing the enzyme were pooled and dialyzed against 20 mM TMA-
HEPES (pH 8.0) containing 3 g.  Chelex resin, 5 mM EDTA, and 1 mM DTT followed 
by dialysis against 20 mM TMA-HEPES (pH 8.0) with 1 mM DTT.  Protein was then 
concentrated and passed isocratically through a 1.6 x 60 cm S100 gel filtration column.  
The protein was dialyzed in 20 mM HEPES (pH 8.0) with 1 mM DTT, concentrated, and 
stored at -80 °C. 
 
Kinetic Analysis of Native and GSH Binding Mutants 
The kinetic assay for native protein was followed as described to determine kinetic 
parameters for mutants.58 Briefly, enzyme was incubated with the appropriate metal(s) 
prior to addition of thiol and fosfomycin (disodium or TMA salt).  Reactions were 
quenched at a time such that less than 20% of the variable substrate was consumed and 
derivatized with a fluorescent reagent (AQC) prior to HPLC analysis.  Data was fit to a 
non-linear Michaelis-Menten curve using GraphPad Prism © to calculate kcat, KM, and 
kcat/KM.  For the K90A and R93A mutations, saturation with GSH was not possible for 
this analysis inasmuch as the maximum practical concentration of GSH in the assay is 
100 mM.  For these mutants a kcat/KMGSH was calculated by fitting the linear portion of 
the curve with a straight line.59  
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Fluorescence Titration of P. aeruginosa FosA with GSH 
 Typically, a solution of 5 µM FosA in the presence of 50 µM MnCl2 and 100 mM 
KCl was prepared in 20 mM TMA-MOPS (pH 8.0) that had been filtered through a 0.2 
µm filter. 
A solution of buffer containing MnCl2 and KCl was prepared similarly. One 
micromolar enzyme was used for the Q36N, Y39F, S50A, K90A and R93A mutants.  
GSH was added to both solutions incrementally while monitoring the change in intrinsic 
protein fluorescence.  Titration measurements were made in triplicate on a SPEX 
Fluorolog-3 spectrofluorimeter (Horiba Jobin-Yvon, Edison, NJ) in the constant 
wavelength mode.  Solutions were excited at 275 nm (3 nm slit width), and emission 
measurements were taken at 340 nm (3 nm slit width) for most mutants.  For the K90A 
and R93A mutants, excitation was at 295 nm (2 nm slit width) and emission was 
measured at 328 nm (4 nm slit width).  This is due to the lower absorbance of GSH at 295 
nm versus 275 nm and the need for much higher concentrations for these mutants.  After 
correction for the inner filter effect of GSH the data were averaged and fit to a hyperbola 
to obtain a Kd. 
 
Minimum Inhibitory Concentration (MIC) for GSH Binding Mutants 
To test whether or not the mutations made in P. aeruginosa FosA affected the 
ability of the enzyme to confer resistance to the antibiotic, the mutant expression 
plasmids were transformed into E. coli and grown on LB plates containing different 
amounts of fosfomycin.  Each plate contained between 0 and 20 mg/mL fosfomycin, 100 
µg/mL ampicillin, and 10 µg/mL glucose-6-phosphate.  Plates were divided into six 
sections to accommodate six different mutants.  For each plate one section was native P. 
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aeruginosa FosA (positive control), another was E. coli transformed with empty vector 
(pET20, negative control), and the other four were various mutants.  For each spot on the 
plate, 30 µL of suspension of bacteria (OD600 = 0.03) in LB/Amp media was added and 
spread onto the plate.  Plates were incubated at 37 °C for 16 hours.  Plates were 
visualized by spraying them with a solution of 0.5 mg/mL thiazolyl blue tetrazolium 
bromide. 
 
Structural Overlay of P. aeruginosa FosA and M. loti FosX 
 The crystal structures for these enzymes have been solved, published, and are 
freely available via pdb.com.40,43 A structural superposition of these enzymes, 1LQP and 
1R9C, was done using the program Chimera (UCSF, San Francisco, CA).   
 
Rational Mutagenesis of the M. loti FosX 
 All PCR reactions were made on the M. loti FosX enzyme already ligated into a 
pET-20 vector.  The initial three mutations made, E44G, F46Y, and M57S, were made by 
Kerry Fillgrove, Ph.D.57 All subsequent mutations were made in the background of this 
triple mutant.  Several successive PCR experiments were run to make several different 
deletions and point mutations in the M. loti FosX Triple Mutant enzyme.  Also, a PCR 
reaction was run to delete residues R99, V100, and E101 in the triple mutant background.  
Subsequently, the entire K+- binding loop from the P. aeruginosa FosA was inserted into 
the M. loti FosX with successive point mutations.  These mutations were R94W, P95K, 
P98R, R103D (by Lauren Beihoffer) as well as L89H, L91V, D92R, and M93E.  Other 
deletion PCR reactions run in the M. loti FosX Triple Mutant K-loop background 
included the deletion of T36, E37, F39, S40, C41, and S42.  The last point mutations 
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made were then S34W/H/Q/N, R43Q, and D27G or R85Q in either the S34Q or the S34N 
backgrounds. 
 
Rational Mutant FosX Expression, Purification, and Activity 
 For each round of PCR the mutant DNA was isolated and sequenced.  DNA with 
the desired sequence was then transformed into BL21 (Gold) DE3 E. coli and plated on 
LB/Amp plates.  Single colonies were selected to inoculate a 200 mL liquid culture of LB 
medium with 100 µg/mL ampicillin.  This culture was grown overnight at 37 ºC with 
shaking at 200 rpm.  The OD600 of the culture was measured and a volume needed to 
make 2 L of LB/Amp with an OD600 = 0.02 was added to 2 L of LB/Amp in a fermentor 
and grown at 37 ºC with constant stirring and aeration.  When the OD600 reached 0.6-0.8 
800 µL of 1 M IPTG was added to induce protein expression.  The culture was allowed to 
incubate for a further five hours. 
 The mutants were purified using the same method as that published for the M. loti 
FosX enzyme.43,58 This is also the same method briefly discussed for the GSH Binding 
mutants.  Activity was checked using the 31P NMR assay.58 
 
In-vitro DNA Shuffling 
 The in-vitro DNA shuffling experiments were performed by Matt Schaab and are 
detailed in the supporting information for Brown et al.56 
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Protein Expression and Purification for the DNA Shuffling Mutants 
      M. loti FosX (E44G/F46Y/M57S)  
 The triple mutant gene was constructed by procedures previously described for 
the E44G mutant.43,44 The protein was expressed and purified following the procedures as 
described for the native M. loti FosX enzyme.43 
      DNA Shuffle Mutants S1.1, S1.2, S2.2 (S3.1) 
Selected plasmids (specifically S1.1, 1.2, and 2.2) obtained from the DNA 
shuffling experiments were used to transform E. coli BL21 (DE3) cells via heat shock 
and spread onto LB plates containing 100 µg/mL ampicillin and incubated overnight at 
37 °C.  Single colonies from these plates were used for expression of the proteins as 
indicated below.  
The S1.1 and S2.2 proteins were expressed and purified as follows.  Single 
colonies were used to inoculate 100 mL of LB containing 100 µg/mL ampicillin. The 
culture was grown overnight at 37 °C with shaking at 225 rpm. Six 1 L portions of LB 
containing 100 µg/mL ampicillin were each inoculated with 10 mL of the starter culture.  
The cultures were grown at 37 °C with shaking at 250 rpm until the OD600 reached 0.8.  
Protein expression was induced by the addition of 100 mg IPTG.  The temperature was 
lowered to 15 °C and cultures were incubated for 20 hr at 150 rpm.  The cells were 
harvested by centrifugation and the cell paste was frozen and stored at -80 °C.  
The cell paste was later thawed and suspended in 100 mL of 50 mM HEPES, pH 
7.5, with 50 mM NaCl, 1 mM EDTA and 1 mM DTT.  The cells were lysed via 4 cycles 
of sonication at 70% maximum output with 3 min on and 3 min off with gentle stirring on 
ice.  The cell debris was removed by centrifugation. 1% (w/v) streptomycin sulfate was 
 29 
added to the supernatant and stirred for 1 hr at 4 °C.  Precipitated material was removed 
by centrifugation and the supernatant was dialyzed overnight against 4 L of 50 mM 
HEPES, pH 7.5, with 50 mM NaCl, 1 mM EDTA, and 1 mM DTT.  The dialyzed protein 
was then loaded on a 2.8 x 18 cm DEAE column that had been equilibrated with the same 
buffer.  The column was washed with 250 mL of buffer and then eluted with a 50 to 400 
mM gradient of NaCl in the same buffer.  The fractions containing the enzyme were 
identified by checking the A280 and by SDS-PAGE, pooled and dialyzed against 4 L of 30 
mM KH2PO4, pH 7.5, with 1 mM DTT.  The protein was concentrated to ~10 mL and 
loaded onto a 2.8 x 6.5 cm hydroxyapatite column that had been equilibrated with the 
phosphate buffer.  The protein was eluted with an isocratic gradient of the same buffer. 
Fractions containing the enzyme were pooled and dialyzed against 4 L of 50 mM 
HEPES, 50 mM NaCl, 1 mM EDTA, and 1 mM DTT.  The protein was concentrated to 
~4 mL and further purified by gel filtration chromatography on a 1.6 x 60 cm Sephacryl 
S-100 HR column.  The purity of the final protein preparation was estimated to be ≥ 98% 
by SDS-PAGE, using 15% Tris-HCl gels.  The protein was dialyzed over night in 20 mM 
TMA-HEPES, pH 7.5 with 5 mM EDTA, 3 g. Chelex resin, and 1 mM DTT, followed by 
another round of dialysis in the same buffer minus the EDTA and Chelex resin.  The 
protein was stored at -80 °C.  
The S1.2 protein was expressed and purified as follows.  Freshly transformed 
cells were streaked on LB agar plates containing 100 µg/mL ampicillin and the plates 
were incubated overnight at 37 °C.  A single colony was used to inoculate 200 mL LB 
containing 100 µg/mL ampicillin.  The culture was incubated overnight at 23 °C with 
shaking at 200 rpm.  Four 15 mL aliquots of the culture was used to inoculate four 1 L 
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portions of LB containing 100 µg/mL ampicillin.  The four 1 L cultures were incubated at 
37 °C with shaking at 250 rpm.  When the OD600 reached 0.6 to 0.8, 400µL of 1 M IPTG 
was added to each 1 L culture (final [IPTG] = 0.4 mM).  The temperature was dropped to 
15 °C and the shaking to 200 rpm and the cultures were incubated overnight.  The cells 
were harvested by centrifugation and the cell pellets were suspended in 20 mM Tris, pH 
7.5, and lysed by sonication in 4 x 3 min cycles with 3 min between cycles.  The lysed 
cells were centrifuged and the lysate was dialyzed overnight against 20 mM Tris, pH 7.5, 
with 1 mM DTT. 
The protein was purified by applying the dialyzed extract to a DEAE column that 
had been equilibrated with 20 mM Tris, pH 7.5.  The column was eluted with a 0-0.4 M 
gradient of NaCl in the same buffer.  The enzyme was detected by checking the fractions 
A280 and running SDS-PAGE on selected fractions.  The pooled fractions containing the 
enzyme were then dialyzed against 20 mM KH2PO4, pH 6.8, with 1 mM DTT and 3 g. 
Chelex resin.  The protein was concentrated to ~10 mL and applied to a hydroxyapatite 
column that was equilibrated with 20 mM KH2PO4, pH 6.8.  The protein was eluted with 
an isocratic gradient of the same buffer.  The fractions containing the enzyme were 
dialyzed overnight against 20 mM Tris, pH 8.0, with 1 mM DTT, 5 mM EDTA and 3 g. 
Chelex resin.  The protein was concentrated to 2-3 mL and 0.5 mL aliquots were applied 
to a MonoQ 4.6/100 PE FPLC column equilibrated with 20 mM Tris, pH 8.0, and eluted 
with a 0 – 0.5 M gradient of NaCl in the same buffer.  The protein eluted as the main 
peak at approximately 0.2 M NaCl.  The protein was dialyzed overnight against 20 mM 
TMA-HEPES, pH 7.5, with 1 mM DTT, 5 mM EDTA, and 3 g. Chelex resin and again 
for 8 hr against a change of the same de-metallating buffer.  The final dialysis was done 
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overnight against 20 mM TMA-HEPES, pH 7.5, with 1 mM DTT. The protein was 
concentrated to ~5 mL and stored at -80 °C. 
 
Minimum Inhibitory Concentration (MIC) Assays for DNA Shuffling Mutants 
 Selected plasmids and the M loti triple mutant were used to transform E. coli 
BL21 (DE3) cells, which were then plated onto LB agar containing 100 µg/mL 
ampicillin. The plates were incubated overnight at 37 °C.  A single colony was then used 
to inoculate 3.5 mL LB containing 100 µg/mL ampicillin.  The liquid cultures were 
grown at 37 °C until the OD600 reached 0.6.  The culture was then diluted to OD600 = 0.03 
and 30 µL was then plated onto LB agar plates containing 100 µg/mL ampicillin, 10 
µg/mL glucose-6-phosphate, and a variable concentration (0 to 1.0 mg/mL) of 
fosfomycin.  The plates were incubated at 37 °C overnight. 
 
Steady-State Kinetics for DNA Shuffling Mutants 
 Reactions were followed with the HPLC-based assay previously reported.37,58 All 
reactions were run at 25 °C in 20 mM TMA-HEPES, pH8.0, containing 50 µM MnCl2 
and 100 mM KCl.  Temperature was maintained using a water bath.  Enzyme 
concentrations were 0.5 µM for reactions with triple mutant, M. loti 
FosX(E44G/F46Y/M57S), 0.3 to 0.4 µM S1.1 and 0.05 to 0.2 µM S1.2.   Reactions were 
carried out with either a fixed concentration of [GSH] = 20 mM and a variable 
concentration of 0.05 to 50 mM fosfomycin or a fixed concentration of [fosfomycin] = 10 
mM and a variable concentration of 0.2 to 100 mM GSH. 
For reactions where fosfomycin was the variable substrate, reactions were 
initiated by addition of 20 µL of fosfomycin to 80 µL of a solution of enzyme, Mn2+, K+, 
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and GSH (E•Mn•K•GSH) using the concentrations listed above.  The reactions were 
incubated for 3 min and quenched with the addition of 200 µL of 5% trichloroacetic acid 
with vortex mixing for 10 s.  The pH was returned to neutral by the addition of 100 µL of 
50 mM NaOH and 100 µL of 1.0 mM valine was added as an internal standard.  For 
reactions where GSH was the variable substrate 20  µL of GSH was added to 60 µL of a 
E•Mn•K solution and the reaction was initiated with the addition of a solution of 20 µL of 
fosfomycin.  The reaction mixture was quenched after 3 min as described above. 
The quenched reaction mixtures were derivatized with the AccQ-Fluor reagent kit 
from Waters (Milford, MA) following the manufacture’s instructions.  A 5 µL aliquot of 
the quenched reaction mixture was added to 80 µL of the supplied borate buffer followed 
by 15 µL of the AccQ-Fluor reagent.  The mixture was heated at 55 °C for 10 min and 
then diluted with 400 µL of HPLC Buffer (140 mM sodium acetate, 12.5 mM 
triethylamine, pH 5 with phosphoric acid).  A 20 µL aliquot of the derivatized solution 
was injected on a Beckman Ultrasphere C18 analytical column.  Samples were eluted 
with HPLC Buffer and a linear gradient of 0 to 30% CH3CN at a flow rate of 1.0 mL/min  
The concentration of the product was determined by the ratio of the peak area of the 
product eluting at 9.1 min to the peak area of the internal standard valine eluting at 14.5 
min using a standard curve.  Each reaction was done in triplicate and the data were fit 
with GraphPad Prism to a hyperbola (in the case of saturation kinetics) or a linear 
function where saturation was not observed.  The triple mutant and the S1.1 and S1.2 
mutants could not be saturated with GSH so that the kcat/KMGSH for these proteins were 
determined from the linear dependence of the initial velocity on [GSH].59 
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31P NMR for Shuffling Mutants 
 The 31P NMR analysis was done using 5 µM enzyme, 50 µM Mn2+, 100 mM K+, 
30 mM fosfomycin, and 100 mM GSH.  One milliliter reactions were set up at 25 ºC and 
allowed to run for anywhere from 5 to 240 minutes.  At designated time points, 300 µL of 
the reaction solution was removed and placed in a new tube containing 50 µL of 
chloroform (CHCl3) and vortexed for 30 s.  The organic layer was removed and discarded 
and the solution was demetallated using a small quantity of Chelex resin (Bio-Rad, 
Hercules, CA).  The solution with Chelex was shaken for two hours and centrifuged.  The 
solution was removed from the resin and put in a standard NMR tube.  The resin was 
washed with 300 µL of D2O and added to the sample.  Data was collected using the auto-
sampler on a Bruker 500 MHz NMR with an 11.7 Tesla Oxford magnet controlled by a 
Bruker DRX-500 Console with a 5 mm Z-gradient QXI probe using a 31P proton 
decoupled pulse program.  Substrate fosfomycin can be identified at δ11 ppm with the 
diol product at δ16 ppm and the GSH bound adduct at δ18 ppm.  A vmax can be estimated 
from the relative peak heights of the substrate and product. 
 
DNA Shuffle Mutant 2.2 Purification and Crystallography 
 DNA shuffle mutant 2.2 was purified using the same procedure as that for 
DNAs1.1 above. 
 Purified enzyme was used in several matrix screens to try to grow crystals.  
Success was achieved finally using an enzyme solution containing 10 mg/mL DNAs2.2, 
2 mM Mn2+, 100 mM K+, and 20 mM fosfomycin and mixing that 1:1 with a solution of 
20% PEG-3350, 100 mM NH4Cl, and 0.4% 1,3-Propanediol in microbatch trays under 
Al's Oil.  Crystals generally grew in 2-3 days.  Data was collected with a Bruker 
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Microstar microfocus rotating-anode X-ray generator with a Proteum PT135 CCD 
detector, with kappa goniometers and a Bruker Kryo-Flex cryostat.  Data was collected at 
100 ºK using a solution of the crystal buffer with 20 % ethylene glycol as a 
cryoprotectant.  Images were processed using HKL-2000.  Phaser was used for the 
molecular replacement phasing using PDB 1R9C (M. loti FosX).  Refmac was then used 
to refine the Phaser output.  ARP/wARP was used to remove model bias, followed by 
further refinement using refmac.  The structure was further modified using Coot, 
followed by further rounds of refinement in Refmac. 
 
Monobromobimane (mBBr) Activity Check 
 To test whether or not mBBr would be a useful compound to detect the presence 
of GSH in enzyme reactions, 2 mL test reactions were run in a fluorimeter. The reaction 
used 200 nM Pa1129 FosA, 50 µM Mn2+, 100 mM K+, 750 µM fosfomycin, and 500 µM 
GSH in 10 mM NaH2PO4, 135 mM NaCl, pH 7.5.  Reactions were run with and without 
enzyme or GSH to check for the presence of fluorescence from the GSH-mBBr 
conjugation product.  The reaction fluorescence was measured with λex = 370 nm and λem 
= 480 nm. 
 
FosA HTS Assay Development: CRC Curve 
 The FosA enzymatic assay was developed using purified enzyme and the known 
inhibitor phosphonoformate (Pf).49 The assay was performed by adding 20 µL of a 
solution containing 500 nM FosA, 125 µM Mn2+, 250 mM K+, and 1.25 mM GSH in 10 
mM NaH2PO4, 135 mM NaCl, pH 7.5 (HTS Buffer) to 20 µL of a solution of Pf of 
varying concentrations (3x serial dilution from 20.25 mM) in HTS Buffer with 0.25% 
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DMSO.  Finally, 10 µL of 3.75 mM fosfomycin in HTS Buffer was added to initiate the 
reaction.  The final concentrations in the reaction were 200 nM FosA, 50 µM Mn2+, 100 
mM K+, 500 µM GSH, 0-8.1 mM Pf, 750 µM fosfomycin, and 0.1% DMSO.  The 
reaction was allowed to run for 60 minutes at room temperature in a covered, black, 384-
well, solid bottom microplate.  After 60 minutes, 10 µL of 1.3 mg/mL 
monobromobimane (mBBr) in acetonitrile was added to give a final concentration of 216 
µg/mL mBBr (800 mM).  The plate was covered with a black lid and the reaction was 
allowed to proceed for 30 min at room temperature.  The fluorescence was then read on a 
Spectramax® M5 microplate reader (Molecular Devices, Sunnyvale, CA) with λex = 370 
nm and λem = 480 nm in top-reading fluorescence mode, sensitivity 6.  Results were fit to 
a sigmoidal curve to calculate and IC50 and IC80 for Pf in this assay using GraphPad 
Prism. 
 
HTS Instrumentation and Validation, Assay ver. 1.0 
 To make sure that this assay would work with the instrumentation available in the 
Vanderbilt HTS Core, a modified version of the enzymatic assay was performed in the 
core lab.  The E•Mn•K•GSH solution, a 20 µL addition, was added to the reaction plates 
using a Thermo-Electron Multi-Drop Combi (Waltham, MA).  The Pf dilutions were 
made in a clear, 384-well polypropylene plate and 20 µL of Pf was added to the reaction 
plate using a Velocity 11 Bravo®, robotic liquid dispensing system (Santa Clara, CA).  
The fosfomycin and the mBBr, 10 µL additions, were also added using the Multi-Drop 
Combi.  All final concentrations are the same as stated above.  The plates are then read 
on a Spectramax M5 microplate reader with the same settings listed above.  Plates were 
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run with varying times allowed for the enzymatic reaction before the addition of mBBr to 
optimize the time course for the assay while maintaining a good IC50 curve. 
 
IC50 and IC80 Z’ Calculations 
 The viability of an assay for HTS is determined by calculating a Z’ value for the 
assay.60 The Z’ was calculated by setting up individual plates of IC50 or IC80 
concentrations of Pf, 60 and 200 µM respectively, in a checkerboard format against a 
buffer control in 384-well plates.  The assay was performed using the exact same reaction 
mechanism as before and the Z’ value was calculated as published. 
 
Initial Compound Screen 
 The assay was tested by screening a small portion of the Vanderbilt Collection of 
compounds.  The compounds from the Vanderbilt Collection, 10 plates (3200 
compounds), were transferred from their storage plates to clear, 384-well polypropylene 
microplates in columns 3-22 (75 nL using a Labcyte Echo® 555 sonic liquid dispensing 
system [Sunnyvale, CA]) and diluted with 30 µL of HTS Buffer.  20 µL of the 
E•Mn•K•GSH solution was added to a black, 384-well polystyrene microplate using the 
Multi-Drop Combi (Note: It is important to keep the enzyme solution on ice to preserve 
maximum functionality).  Twenty microliters of the compound solutions were then 
transferred from the clear polypropylene plate to the black polystyrene plate using the 
Velocity 11 Bravo.  Columns 1, 2, 23, and 24 are used to make checkerboards of IC50 
concentrations of Pf, 60 µM, and a buffer control by adding 1 µL of either Pf or buffer.  
After the enzymatic reaction incubated at room temperature for 30 minutes, the plates 
were read on the Spectramax M5 before the addition of mBBr.  Once mBBr was added, 
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and the reaction allowed to run 30 min, the plates were read again, and the difference was 
taken between the two reads (Figure 15a). Hits are identified as compounds with a greater 
than three standard deviation in signal strength above the average (taken from all wells in 
columns 3-22) on an individual plate. 
 
Hit Confirmation 
 To verify the hits identified in the compound screen, the compounds were ordered 
from ChemBridge.  New 10 mM stocks were made for each compound in pure, 
anhydrous DMSO.  One hit compound, CB5838696, was no longer available from 
ChemBridge, but four closely related structural analogs were available and they were 
used in the confirmation screen (CB5844324, CB5848410, CB5846450, and 
CB5838937).  All 104 compounds identified as hits were arranged on a clear, 384-well, 
low volume microplate and the assay was performed as before.  In addition to the normal 
assay, assays were done with 3x concentrations of test compounds and, also, in the 
absence of glutathione. 
 
HTS Assay Version 2 
 This assay was done by adding 40 µL of a E•Mn•K•GSH solution (250 nM 
enzyme, 62.5 µM Mn2+, 125 mM K+, 625 µM GSH) to a black, 384-well polypropylene 
microplate and then immediate addition of the library compounds, 50 nL, to the same 
plate using the Echo 555.  One µM Pf was then added manually to columns 1, 2, 23, and 
24 in a checkerboard format against DMSO.  The plate was incubated at room temp. for 
10 min followed by the addition of 10 µL of fosfomycin with the Combi to start the 
reaction.  The rest of the assay, post addition of fosfomycin, was run in the same manner 
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as the previous version of the assay except that the mBBr was dissolved in methanol 
instead of acetonitrile for better chemical stability in the microplates (Figure 15b).  In 
addition, instead of picking hits on a per-plate basis, a population based hit picking 
scheme was used.  All results were normalized to a % max signal of the positive control 
for each plate and then the average and standard deviation was calculated for all 
compounds screened (3200 total).  Hits were identified as compounds with a % max 
signal greater than three standard deviations above the mean. 
 
Hit Confirmation, Version 2 
 Hits from the second version of the assay were verified by ordering new 
compounds from the supplier and making new 100 mM or 50 mM stocks, depending on 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 15: A) Workflow for assay version 1.  B) Workflow for assay version 2.  Version 
3 is run the same way as version 2 but with the Zn standard added using the Echo 555. 
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solubility.  CRC profiles were then created of the hits to confirm activity.  See CRC 
profile method below. 
 
Compound Screen, Assay Version 3 
 
 The positive standard used was a 5 mM ZnCl2 solution in DMSO.  Fifty 
nanoliters of this solution was added to the reaction plates with the Echo 555 immediately 
prior to the addition of the library compounds.  All other steps proceed in the same 
manner as in assay version 2. 
 
CRC Profile for Confirmed Hits 
 CRC curves of the confirmed hits were created by making 50 or 100 mM stock 
solutions of the compounds in DMSO, depending on solubility, and using the same assay 
procedure as the screen.  A 3x dilution of each compound was made in quadruplicate in a 
clear, 384-well microplate. The assay was run as before and the data was fit to a 
sigmoidal curve using GraphPad Prism. 
 
Compound Binding Titrations, Kd 
 Compound binding constants, Kd, were calculated by titrating compounds into a 
solution of 1 µM enzyme, 50 µM Mn2+, 100 mM K+, in 20 mM TMA MOPS, pH 7.5, 
and monitoring the changes in intrinsic protein fluorescence with λex = 275 nm and λem 
=330 nm.  Fluorescence titrations were done in a FluorLog-3 spectrofluorimter by Horiba 
Jobin-Yvon (Edison, NJ).  Data was fit to a hyperbolic function to calculate the Kd after 
correction for the inner filter effect of the compounds.61 
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Figure 16: Synthetic Scheme for the synthesis of the various derivatives of CB 5838696, 
numbered kk-5-series by the Vanderbilt Chemical Synthesis Core.  The derivatives were 
made by substituting the appropriate benzaldehyde in the final synthetic step. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17: Synthetic schemes for all four members of the kk-8-series of compounds, all 
made in one step reactions. 
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 Compound Synthesis and Activity 
 All compound synthesis was done by Dr. Kwangho Kim in the Vanderbilt 
Chemical Synthesis Core. 
      Synthesis of (E)-ethyl 3-(2-carbamothioylhydrazono)butanoate 
 
 A suspension of ethyl acetoacetate (1.0 mL, 7.91 mmol), thiosemicarbazide 0.72 
g, 7.91 mmol), and piperidine (0.1 ml) in methanol (10 mL) was irradiated at 120 ºC for 
15 min by microwave. The solvent was evaporated in vacuo and solid product 2 (1.21 g, 
75 %) was obtained by flash column chromatography on silica gel (hexane/ethyl acetate, 
2/1 v/v).  1H NMR (DMSO, 400 MHz) δ (ppm) 10.29 (br s, 1H), 8.12 (br s, 1H), 7.58 (br 
s, 7.58), 4.09 (q, J = 7.2 Hz, 2H), 3.30 (s, 2H), 1.94 (s, 3H), 1.18 (t, J = 7.2 Hz, 3H); 
LCMS, single peak, 1.86 min, m/z, 204.1 (M+1). 
      Synthesis of (E)-ethyl 3-(2-(4-(4-fluorophenyl)thiazol-2-yl)hydrazono)butanoate 
 To a solution of (E)-ethyl 3-(2-carbamothioylhydrazono)butanoate 2 (1.21 g, 5.95 
mmol) in ethanol/DMF (5 mL/5 mL) was added 2-bromo-1-(4-fluorophenyl)ethanone 
(1.29 g, 5.95 mmol) at room temperature. The reaction mixture was stirred for 2 h at 
room temperature. The precipitated product was filtered and washed with hexane (3 x 10 
mL) to provide white solid product 3 (1.41 g, 74%). 1H NMR (CDCl3, 400 MHz) δ (ppm) 
7.74-7.70 (m, 2H), 7.18 (t, J = 8.4 Hz, 2H), 6.68 (s, 1H), 4.20 (q, J = 7.2 Hz, 2H), 3.42 (s, 
2H), 2.29 (s, 3H), 1.29 (t, J = 7.2 Hz, 3H); LCMS, single peak, 3.36 min, m/z, 322.8 
(M+1). 
      Synthesis of 1-(4-(4-fluorophenyl)thiazol-2-yl)-4-methyl-1H-pyrazol-5(4H)-one 
 A suspension of (E)-ethyl 3-(2-(4-(4-fluorophenyl)thiazol-2-
yl)hydrazono)butanoate 3 (1.41 g, 4.39 mmol) and piperidine (0.1 mL) in methanol 
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(7mL) was irradiated at 100 ºC for 15 min by microwave. The solvent was evaporated in 
vacuo affording crude solid that was purified by flash column chromatography on silica 
gel (MeOH/CH2Cl2 = 1/10) to provide 4 (1.08 g, 90 %) 1H NMR (CDCl3, 400 MHz) δ 
(ppm) 7.95-7.85 (m, 1H), 7.80-7.75 (m, 1H), 7.19-7.05 (m, 3H), 3.53 (s, 2H), 2.30 (s, 
3H); LCMS, single peak, 2.92 min, ``m/z, 276.8 (M+1). 
      Synthesis of kk-5-series Final Products 
 A mixture of 1-(4-(4-fluorophenyl)thiazol-2-yl)-4-methyl-1H-pyrazol-5(4H)-one 
4 (100 mg, 0.36 mmol), 4-hydroxybenzaldehyde (54 mg, 0.36 mmol) and anhydrous 
sodium acetate (36 mg, 0.44 mmol) were suspended in acetic acid (4 mL) and irradiated 
at 120 ºC for 15 min by microwave. The reaction mixture was filtered and the filtrate was 
poured on crushed ice. The solid product kk-5-033 (R = para-OH)(Figure 16), (54 %) 
obtained, was crystallized from ethanol. Compounds kk-5-095-2, kk-5-095-5, kk-5-141-
1, and kk-5-141-2 were also synthesized by the similar method using appropriate 
benzaldehydes, Figure 16. 1H NMR (DMSO, 400 MHz) δ (ppm) 8.54 (d, J = 8.4 Hz, 2H), 
7.98-7.92 (m, 2H), 7.34 (s, 1H), 7.15 (s, 1H), 7.05 (t, J = 6.5 Hz, 2H), 6.72 (d, J = 9.2 Hz, 
2H), 3.14 (s, 6H), 2.41 (s, 3H); LCMS, single peak, 3.74 min, m/z, 407.8 (M+1). 
      Synthesis of kk-8-054 
 To a solution of 2-methoxyaniline (0.11 mL, 0.94 mmol) in DMF (4 mL) was 
added diisopropylethylamine (0.41 mL, 2.34 mmol), 2-(thiophen-2-yl)quinoline-4-
carboxylic acid (0.20 g, 0.78 mmol), and followed by PyBOP (0.45g, 0.86 mmol). The 
reaction mixture was stirred for 5 h at room temperature then solvent was removed in 
vacuo and white solid product (0.20 g, 71 %) was obtained by flash column 
chromatography on silica gel (hexane/ethyl acetate, 2/1 v/v)(Figure 17). 1H NMR 
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(CDCl3, 400 MHz) δ (ppm) 8.62 (d, J = 7.6 Hz, 1H), 8.36 (s, 1H), 8.24 (d, J = 8.0 Hz, 
1H), 8.15 (d, J = 8.4 Hz, 1H), 7.97 (s, 1H), 7.78-7.73 (m, 2H), 7.56 (t, J = 8.0 Hz, 1H), 
7.51 (d, J = 4.8 Hz, 1H), 7.20-7.15 (m, 2H), 7.09 (t, J = 7.6 Hz, 1H), 6.95 (d, J = 8.0 Hz, 
1H), 3.87 (s, 3H); LCMS, single peak, 1.49 min, m/z, 361.2 (M+1). 
      Synthesis of kk-8-056 
 A mixture of 5-(4-bromophenyl)furan-2-carbaldehyde (200 mg, 0.80 mmol), 
barbituric acid (102 mg, 0.80 mmol) and anhydrous sodium acetate (79 mg, 0.96 mmol) 
were suspended in acetic acid (2.7 mL) and irradiated at 120 ºC for 15 min by 
microwave. The reaction mixture was poured on crushed ice and filtered to provide 
orange solid product (274 mg, 95 %)(Figure 17). 1H NMR (DMSO, 400 MHz) δ (ppm) 
8.52 (d, J = 4.0 Hz, 1H), 8.09 (s, 1H), 7.90 (d, J = 8.4 Hz, 2H), 7.73 (d, J = 8.4 Hz, 2H), 
7.49 (d, J = 4.0 Hz, 1H); LCMS, single peak, 1.37 min, m/z, 362.7 (M+1). 
      Synthesis of kk-8-058 
 To a solution of 4-(1H-benzo[d]imidazol-2-yl)aniline (100 mg, 0.48 mmol) in 
dichloroethane (4.5 mL) was added diisopropylethylamine (0.25 mL, 1.44 mmol), (E)-3- 
(furan-2-yl)acrylic acid (79 mg, 0.67 mmol), and followed by PyClU (0.23g, 0.72 mmol). 
The reaction mixture was stirred for overnight at room temperature then solvent was 
removed in vacuo and yellow solid product (77 mg, 49 %) was obtained by flash column 
chromatography on silica gel (hexane/ethyl acetate, ½ v/v)(Figure 17). 1H NMR (DMSO, 
400 MHz) δ (ppm) 10.43 (s, 1H), 8.12 (d, J = 8.4 Hz, 2H), 7.85 (d, J = 8.8 Hz, 3H), 7.63 
(d, J = 7.2 Hz, 1H), 7.49 (d, J = 7.2 Hz, 1H), 7.42 (d, J = 15.6 Hz, 1H), 7.17 (q, J = 6.0 
Hz, 2H), 6.88 (d, J = 3.2 Hz, 1H), 6.69-6.61 (m, 2H); LCMS, single peak, 1.18 min, m/z, 
330.7 (M+1). 
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      Synthesis of kk-8-060 
 A suspension of 1-(adamantan-1-yl)-2-bromopropan-1-one (200 mg, 0.74 mmol) 
and acethyl thiourea (262 mg, 2.22 mmol) in NMP was irradiated at 70 ºC for 30 min by 
microwave. The cooled solution was diluted with water. The product was filtered, 
washed with methanol and dried in vacuo to afford a white solid product (142 mg, 66 %) 
(Figure 17). 1H NMR (CDCl3, 400 MHz) δ (ppm) 2.45 (s, 3H), 2.19 (s, 3H), 2.03 (bs, 
9H), 1.75 (bs, 6H); LCMS, single peak, 1.49 min, m/z, 291.7 (M+1). 
 
Zn Analysis by Neutron Activation 
 Five ChemBridge compounds, 5839909, 5992599, 6106988, 5847158, and 
7433453 were sent to Elemental Analysis, Inc. (Lexington, KY) to be tested for zinc 
concentration.  Elemental Analysis elected to use Neutron Activation Analysis.  This 
technique uses radiation to form a radioactive nucleus in the sample.  The identity of an 
element, like zinc, can then be determined based on the element's specific decay.  The 
amount of zinc present in the sample can be calculated based on the intensity of the 
gamma ray emission.62 
 
Zn Inhibition HPLC Assay 
 This uses the same conditions as the HTS assay.  The final concentrations used 
were 200 nM Pa1129 FosA, 50 µM Mn2+, 100 mM K+, 500 µM GSH, 750 µM 
fosfomycin, and 0.1% DMSO in HTS Buffer (10 mM NaH2PO4, 135 mM NaCl, pH 7.5) 
with a final reaction volume of 100 µL.  The reaction was allowed to run at room 
temperature for 30 min and then quenched by the addition of 200 µL of 5% TCA with 
vortexing.  The pH was re-adjusted to neutral with 100 µL of 800 mM NaOH with 
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vortexing.  An internal standard, 100 µL of 1 mM valine, was then added.  A portion of 
the reaction, 15 µL, was then added to 70 µL borate buffer and then derivatized using 15 
µL of the AccQ-Fluor Reagent from Waters.  The sample was then diluted with 400 µL 
of HPLC buffer (140 mM sodium acetate, 12.5 mM triethylamine, pH 5 with phosphoric 
acid).  The diluted reaction mixture was then applied to a 4.5 cm x 25 cm ultrasphere 
reverse phase column (Beckman-Coulter) and eluted with a 0-30% acetonitrile gradient.  
The concentration of product in the reaction was determined based on the ratio of the 
product peak to the internal standard, valine. 
 
NMR Analysis of ChemBridge and kk-5-series of Compounds 
 Compounds CB 5848410, CB 5846450, kk-5-095-1, kk-5-095-3 (kk-5-141-1), kk-
5-095-4 (kk-5-141-2), and kk-5-095-5 were analyzed by 1H, COSY, HSQC and HMBC 
NMR in d6-DMSO.  Data was collected on a 600 MHz Bruker NMR with a 14.1 Tesla 
Bruker magnet controlled by a Bruker AV-II console with a 5 mm Z-gradient TCI Cryo-
probe.  Data was analyzed using TopSpinTM by Bruker. 
 
Resazurin Bioactivity Assay 
 E. coli BL21 Gold (DE3) cells were transformed with either FosA in a pET-20b 
vector or empty pET vector.  Single colonies were used to inoculate 5 mL LB/Amp 
cultures and grown at 37 °C with shaking.  The OD600 was measured in a 
spectrophotometer and appropriate dilutions were made before using the cultures in 
reaction plates. 
 To test the viability of this assay, checkerboards were set up in clear, 96-well, 
microplates (Whatman, Florham Park, NJ).  For the reaction, 120 µL of LB/Amp/G6P 
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was added to the plate (130 µL for empty vector pET-20 plates).  To this was added 10 
µL each of 1.5 M fosfomycin (FosA only), 15 mM resazurin, and live cells in LB/Amp 
with an OD600 = 0.3.  A checkerboard pattern was set-up in each plate using either sterile 
water or antibiotic (50 mg/mL kanamycin for FosA and 1.5 M fosfomycin for pET-20).  
The final concentrations in each well were 100 µg/mL ampicillin, 500 µM glucose-6-
phosphate (G6P), 100 mM fosfomycin, 1 mM resazurin, 3 mg/mL kanamycin (5.4 mM), 
and the final cell density was OD600 = 0.02, or 5 x 106 colony forming units per milliliter 
(cfu/mL).  Growth was monitored both colormetrically and spectrofluorometrically.  
Plates were covered with a clear plate sealer (SealPlate®, Excel Scientific, Wrightwood, 
CA) and grown at 37 °C with shaking overnight.  Fluorescence was measured in a 
Spectramax M5 microplate reader in top reading fluorescence mode, sensitivity 6, with 
λex = 530 nm and λem = 590 nm.  Z’ values were calculated as before. 
 Cell viability with validated hit compounds from the FosA assay was done by 
adding compounds, in a 2x serial dilution, to plates with either FosA or empty vector 
pET-20 transformed cell lines.  This assay was a slightly modified version of the one 
used by Sarker, et al.57 For each plate, row A was used as a sterility control – no bacterial 
cells added.  Row B was used as a negative control – cells are added but no potentially 
cytotoxic compounds are included.  Rows C-F were used for the compound serial 
dilutions.  Row G was used for a Pf dilution control.  Row H was used for a 2x serial 
dilution of kanamycin as a positive control.  Volumes used were as previously stated.  
Fluorescence readings were taken every two hours for twelve hours and again at 24 
hours. 
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Attempts to Create a FosX HTS Assay 
 Several attempts were made to develop a HTS assay using the purified L. 
monocytogenes FosX.  Protein was purified as published.44 
      Assay using 3-(dansylamino)phenyl boronic acid (DAPBA). 
 Test reactions were run using 150 µM DAPBA dissolved in either methanol or 
ethanol (Figure 18).  Five different buffer systems were tested: 20 mM TMA HEPES, pH 
8, 10 mM NaH2PO4 with 135 mM NaCl, pH 7.5, 20 mM Tris, pH 7.5, and 20 mM 
KH2PO4, pH 6.8, and 25 mM TMA MOPS, pH 7.5.  Molar equivalents of purified fos-
diol was used to check for signal difference between solutions with and without product.  
Data was collected using a FluorLog-3 spectrofluorimter with λex = 337 nm and scanning 
the emission spectra from 450-600 nm. 
      Assay using 8-quinoline boronic acid (8-QBA). 
 A similar test was done using 8-QBA, which should give a concentration 
dependent signal (Figure 18).63 Reactions were run using molar equivalents of 8-QBA 
and purified fos-diol from 500 µM to 20 mM in 100 mM KH2PO4, pH 7.5.  The 8-QBA 
was dissolved in pure methanol and dilutions were made so that the final MeOH 
concentration was 25% in all reactions.  Reactions were run on the FluorLog-3 
spectrofluorimeter with λex = 314 nm and scanning emission wavelengths from 330-530 
nm. 
 
Adrenaline Based FosX Activity Assay 
 This assay measured the amount of fos-diol indirectly and was a modified version 
of the one published by Wahler and Reymond and was run in clear 96-well plates (Figure 
19).64,65 The reaction was done by adding 10 µL of fosfomycin and 10 µL of inhibitor 
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solution to 160 µL of E•Mn to give final concentrations of 500 nM L. monocytogenes 
FosX, 100 µM Mn2+, 1.5 mM fosfomycin, and 0-10 mM Pf.  The reaction was allowed to 
run for one hour and then 10 µL of NaIO4 was added to give a final concentration of 750 
µM NaIO4 and the oxidation reaction was allowed to run for another hour.  At the end of 
that hour 10 µL of adrenaline was added to give a final concentration of 1.5 mM and the 
plates were allowed to stand at room temperature for 30 minutes.  The A490nm was 
recorded using a Spectramax M5 microplate reader. 
 
Gallocyanine Based FosX Assay 
 The gallocyanine assay is run in exactly the same manner as the adrenaline assay; 
only the final signal is read spectrofluorometrically instead of spectrophotometrically, 
making it more sensitive (Figure 20).  Since this assay is more sensitive than the 
adrenaline based absorbance assay, the final concentration of fosfomycin was dropped to 
500 µM, and the final NaIO4 and gallocyanine concentrations were dropped to 300 µM.  
The concentrations of enzyme and metal remained the same as did the reaction times.  
Plates were read on a Spectramax M5 microplate reader with λex = 370 nm and λem = 600 
nm.  Phosphonoformate was used to develop both the adrenaline and gallocyanine assays.  
Other potential inhibitors were also tried.  These include other small phosphonates like 
Ethylphosphonic acid (EPA), Phosphonoacetic acid (PAA), 2-Carboxyethylphosphonic 
acid (CEPA), ethyldiethoxyphosphinyl formate, Tris(trimethylsilyl) phosphite, 
ethoxycarbonyl phosphate (ECP), and acetyl phosphonate, metal chelators such as 
adenosine mono-, di-, and triphosphate (AMP, ADP, ATP), EDTA, EGTA, ADA, citrate, 
HEDTA, BAPTA, oxalate, as well as inactive metals like zinc. 
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PHOME FosX Kinetics Assay 
 PHOME can be used in HTS formats for the discovery of inhibitors to 
mammalian soluble epoxide hydrolases.66 To test this reaction in relation to the L. 
monocytogenes FosX, 1 µM of enzyme was incubated in black 96-well microplates 
(Whatman) with 50 µM Mn2+ and a 2x serial dilution of PHOME (50 µM max).  
Fluorescence measurements were taken every 10 minutes for two hours with λex = 316 
nm and λem = 460 nm on a Spectramax M5 microplate reader.  One half of the 96-well 
plate contained enzyme and the other half did not to act as a control since this reaction 
can occur spontaneously.  For each concentration of PHOME, the enzymatically-
catalyzed signal was determined by subtracting fluorescence values from the negative 
control from the enzymatic reaction.  The data in counts per second (cps) was converted 
to product concentration using a standard curve, plotted vs. time, and fit to a linear line of 
best fit.  The slope of that line gave a rate of reaction for each starting PHOME 
concentration.  A plot of [PHOME] vs. Rate (mM/min) was fit to a Michaelis-Menton 
curve to obtain a kcat and KM for the reaction. 
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Figure 18: A-B) Theory behind the potential fluorescent boronic acid assay.  C) 
Structure of DAPBA.  D) Structure of 8-QBA. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Adrenaline based assay.  A) With no inhibitor present all of the periodate will 
be used up oxidizing the fos-diol product.  The addition of adrenaline will result in no 
change in absorbance.  B) With an inhibitor present, the periodate will not react with 
anything until the addition of the adrenaline for form adrenochrome.  The production of 
adrenochrome can be monitored at 490 nm. 
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Figure 20: Gallocyanine based assy.  This assay works the same as the adrenaline-based 
assay, Figure 59, but with a fluorescent reporter.  The production of oxidized 
gallocyanine can be measured with λex = 370 nm and λem = 600 nm. 
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CHAPTER III 
 
GLUTATHIONE BINDING IN P. aeruginosa FOSA  
AND THE ROLE OF THE K+-BINDING LOOP  
 
Results 
 
GSH Docking and Minimization 
 A putative GSH binding site was first identified by manual docking of GSH onto 
the P. aeruginosa FosA enzyme.  This was followed by energy minimization of the 
docked complex.55 Based on this model, amino acids within hydrogen bonding or 
electrostatic interactions to GSH include W34, Q36, Y39, S50, K90, and R93.  Other 
residues within van der Waals contact distance include C48, Y62, H64, Q91, R119, and 
Y128.  The distance from the GSH thiol group to the C1 position of fosfomycin is 3.48 
Å.  The details can be seen in Figures 21 and 22. 
 
Kinetic Analysis of Native and Mutant Enzymes 
 The GSH molecule is normally activated for nucleophilic attack by ionization 
using assistance from an active site tyrosine or serine in canonical GSH transferases.67 
There were two early candidates to perform this ionization reaction, Y39 and S50.  The 
model showed the hydroxyl group of Y39 3.45 Å from the GSH thiol group, indicating 
that it would be the more likely residue to perform this function.  Indeed, the S50A 
mutation showed very little effect on catalysis but a large effect on the KdGSH indicating 
that it is most likely involved in GSH binding, but not activation.  The conservative Y39F 
mutation showed a 13-fold reduction in kcat and a 50-fold decrease in kcat/KMGSH (Figure 
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Figure 21: FosA residues that bind directly to GSH. 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 22: Ribbon diagram showing GSH bound in FosA.  Primary sphere residues are 
shown in yellow.  Second sphere residues are shown in cyan.  Mn is in purple and K is in 
blue.  Made by Eric Dawson. 
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23).  This is a strong indication that Y39 is involved in the ionization of GSH to form the 
thiolate anion required for activity. 
 The model also suggests that W34, Q36, K90, and R93 are also within either 
hydrogen bonding or electrostatic bonding distance to the terminal carboxylate oxygens 
of GSH.  In fact, the mutation of each of these residues results in a significant loss of 
activity in the FosA mutant enzymes. 
 
GSH Binding Titrations with FosA 
 The titration of FosA with GSH results in a change in the enzymes intrinsic 
protein fluorescence, which can be monitored as a function of [GSH] to determine an 
equilibrium disassociation constant, KdGSH.  The P. aeruginosa FosA has a KdGSH similar 
to the structurally unrelated canonical GSH transferases, around 130 µM.38 The putative 
GSH binding mutants, however, all show a greatly elevated KdGSH (Figure 24).  The 
Q36N, Y39F, S50A, K90A, and R93A mutants show a 150-400 fold increase in their 
KdGSH as compared to the native FosA enzyme.  No KdGSH could be calculated for the 
W34A mutant due to the instability of the enzyme. 
 Two residues, K90 and R93, reside at the base of the K+-binding loop.  The FosA 
enzymes are activated 100-fold by K+ and other monovalent cations.38 It is notable that 
the K90A and R93A mutants have similar kinetic profiles to the native FosA enzyme 
when tested in the absence of K+.  To test this further a K+-binding mutant was created 
with a three amino acid insertion (RVE was inserted between R93 and S94, in the 
position where those residues are located in the M. loti FosX enzyme).  The catalytic and 
binding properties of this insertion mutant were similar to both the K90A and R93A 
mutants as well as the native mutant in the absence of K+. 
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Figure 23: A-D) Fosfomycin kinetics curves.  A, C, and D fit to partial substrate 
inhibition curves.  B fit to Michaelis-Menten curve.  E-I) GSH Kinetic curves.  E, F, H, 
and I fit to linear regression curve to estimate kcat/KM directly. G fit to Michaelis-Menten 
curve. 
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Figure 24: A-E) Changes in intrinsic protein fluorescence upon GSH binding for Pa1129 
GSH binding mutants.  All data were fit to one-site binding hyperbola in Prism. 
 
 
 
 
 
Table 1: Summary of all kinetic data for Pa1129 GSH binding mutants. 
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Enzyme kcat (s-1)b kcat/KMGSH (M-1s-1) KdGSH(mM)a kcat/KMfos (M-1s-1)a MIC100(mg/mL)a
FosAPA 180 ± 6 (4.1 ± 0.8) x 104 .13 ± .03 (9.0 ± 1) x 105 >20
FosAPA -K+ ~10 62 ± 2 39 ± 3 (1.4 ± 0.3) x 103 n.d.
FosAPA -K-loopc ~14 26.6 ± 0.5 39 ± 2 (1.0 ± .2) x 104 2
W34A 32 ± 3 (2.0 ± 0.4) x 102 n.d. (2.1 ± 0.5 )x 104 <1
W34H 30 ± 4 (5.4 ± 1.1) x 103 .10 ± .02 (1.1 ± 0.3) x 104 >20
Q36N 109 ± 3 (1.4 ± 0.1) x 104 32 ± 3 n.d. 4
Y39F 14 ± 2 (8.7 ± 1.0) x 102 21 ± 1 (5 ± 3) x 105 1
S50A 134 ± 2 (6.2 ± 0.4) x 104 60± 3 (1.8 ± 0.9) x 106 2
K90A ~30 (3.4 ± 0.2) x 102 22 ± 3 (2.4 ± 0.9) x 104 2
R93A ~30 (1.9 ± 0.1) x 102 23 ± 3 (3 ± 1) x 104 2
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 The role of the W34 amino acid is more difficult to discern.  The W34A mutant 
has a 30-fold decrease in the kcat/KMGSH, consistent with a role in binding GSH, as 
predicted by the model.  However, the protein precipitated at relatively low [GSH] in 
fluorescence titration experiments, which prohibited the calculation of a KdGSH for this 
mutant enzyme.  Replacing the tryptophan with a histadine restores near native catalytic 
properties.  The W34H mutant theoretically puts the imidazole NH group in a similar 
position as the original tryptophan.  This mutant was stable and MIC results indicate that 
the imidazole is able to bind GSH effectively. 
 The S50A and Q36N mutants show quite different behavior from the other 
mutants.  Both of these enzymes have a KdGSH similar to the other mutants, however they 
have near native kcat/KMGSH.  It is not known why this apparent paradox persists. 
 All of the single point mutations in the GSH binding site have a smaller effect on 
the catalytic efficiency of the enzyme with respect to fosfomycin (Table 1).  This is 
consistent with the fact that all of these residues are thought to be involved in GSH 
binding, not in the recognition and binding of fosfomycin.  The largest changes seen were 
for the K+-binding loop mutant and the native mutant in the absence of K+.  This may 
suggest a larger role for K+ in the activity of FosA. 
 
Efficacy of FosA and Mutants in E. coli 
 The efficacy of the native FosA and mutant enzymes was tested by measuring 
how well they confer resistance to fosfomycin when transformed into E. coli (Figure 25).  
The native bacterium is very sensitive to fosfomycin with a MIC100 < 0.025 mg/mL on 
LB/agar/fos plates.37 The native FosA enzyme can confer resistance to fosfomycin at 
greater than 20 mg/mL, which is the saturation limit of fosfomycin in agar plates.  All of 
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the GSH-binding mutants show a significant decrease in their ability to confer resistance 
in E. coli.  The largest changes were seen for the carboxylate oxygen binding residues, 
W34A, Y39F, K90A, R93A, and for the K+-binding loop mutant.  The W34A and Y39F 
mutants have an MIC less than 1 mg/mL while the K90A, R93A and K+-binding loop 
mutants all have MIC values less than 2 mg/mL.  The Q36N and S50A mutants show a 
greatly depressed MIC despite their enhanced kinetic abilities as compared to the other 
mutants.  The W34H mutant has a native FosA like MIC. 
 There seems to be a loose correlation between the kcat/KMGSH and the MIC values 
for the FosA mutants.  Typically, mutants with a kcat/KMGSH less than 103 have low MIC 
values while those with a kcat/KMGSH greater than 103 have higher MIC values.  Two of 
these mutants do not follow this correlation, however.  The S50A and Q36N mutants 
have high kcat/KMGSH values, but low MIC values.  Both of these mutants also have high 
turnover numbers, but also have high KdGSH. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25: MIC plates for Pa1129 binding mutants.  Plates were sprayed with thiazolyl 
blue before imaging to better visualize the bacterial growth. 
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Discussion 
Model of the GSH-Binding Site 
 The GSH binding model suggests that there are six amino acids within hydrogen 
bonding or electrostatic interaction distance as well as another six amino acids within van 
der Waals contact.  The model was tested experimentally by creating single point 
mutations of the putative binding residues and testing them for their kinetic profiles and 
substrate binding affinity, as well as their ability to confer resistance to fosfomycin when 
transformed into E. coli.  Of the six amino acids tested, two, W34 and Y39, were 
designated as essential to function and one, K90, as "near-essential" by a saturation 
mutagenesis study published previously.54 This is in keeping with the proposed role of 
these amino acids in the enzyme based on the model.  The S50 and R93 amino acids were 
deemed non-essential, as they were able to tolerate several mutations at these positions.  
Q36 was not among the positions tested.  It is also interesting to note that residues within 
van der Waals contact distance, H64 and R119, were deemed essential and C48 and Y128 
were deemed "near-essential".  This indicates that several of the residues indicated in the 
model are essential for enzyme function. 
 
Activation of GSH 
 The P. aeruginosa FosA has several tyrosine residues in the active site that may 
facilitate in the ionization of GSH.  The primary residue is Y39, whose hydroxyl group is 
3.45 Å from the GSH sulfhydryl (Figure 26).  Tyrosine 39 is also conserved in the FosB 
proteins which ionize L-cysteine, or possibly bacillathiol, for addition to fosfomycin.41 
Data from the canonical GSH transferases suggest that active site tyrosine residues can 
lower the pKa of the GSH thiol group, aiding in the formation of the active thiolate 
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anion.67 This interaction is usually assisted by hydrogen bonding interactions with other, 
secondary amino acids.  Tyrosine 128 is in a position to form a hydrogen bond with Y39, 
according to the model.  Tyrosine 128 was previously identified as a "near-essential" 
amino acid and is conserved in the FosA enzymes.54 Other tyrosines that could contribute 
are Y62 and Y100.  These two tyrosines are conserved among all members of the 
fosfomycin resistance protein family and play a role in fosfomycin binding.49 There is no 
evidence that these residues participate in the binding or activation of GSH. 
 
Relationship Between GSH and K+ Binding 
 In the model of GSH binding in FosA, there are five other amino acids in 
hydrogen bonding or electrostatic interactions with GSH other than Y39.  These five 
residues are W34, Q36, S50, K90, and R93.  Serine 50 forms a hydrogen bond with the 
carbonyl at the γ-glutamate linkage to the cysteine of GSH.  While the S50A mutant does 
show an elevated KdGSH consistent with its role in binding GSH, the mutation does not 
seem to effect the catalytic ability of the enzyme. 
   The other four amino acid contacts are responsible for bonding interactions with 
the two terminal carboxylates of GSH.  Glutamine 36 does seem to bind GSH based on 
the catalytic profile of the Q36N mutant, showing an elevated KdGSH.  The Q36N 
mutation, however, does not seem to effect catalysis, but does result in a loss of ability to 
confer resistance to fosfomycin.  Tryptophan 34 seems to be structurally important to the 
enzyme as the W34A enzyme proved to be unstable in GSH titration experiments.  The 
W34H mutant indicates that a hydrogen bond donor at this position is necessary for 
proper function, but that the donor does not necessarily have to be tryptophan. 
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 The K90 and R93 amino acids are particularly interesting.  These two residues 
reside at the base of the loop responsible for binding the monovalent K+ ion (Figure 27).  
The model of GSH binding suggests that these two amino acids ion-pair with the terminal 
carboxylate of the γ-glutamate of GSH.  The proximity of these residues to the K+-
binding loop may indicate a connection between K+ and GSH binding.  The mutation of 
either of these residues, the mutational disruption of the K+-binding loop (RVE insertion), 
or the absence of K+ in reactions with the native enzyme all lead to very similar decreases 
in KdGSH, kcat/KMGSH, and in their ability to confer resistance to fosfomycin when 
transformed into E. coli.  It has been known for some time that the addition of K+ to FosA 
is necessary for maximum function, but the exact role of K+ in the reaction has remained 
elusive.   
 The crystal structure of the P. aeruginosa FosA enzyme seems to indicate that the 
K+ may aid in orienting fosfomycin in the active site of the enzyme.40 This hypothesis 
was bolstered by the observation that in the crystal structure of the Listeria 
monocytogenes FosX with the diol product bound the product is bound in a 180º opposite 
orientation to the substrate bound in the P. aeruginosa FosA.44 The results presented here 
indicate that the role of K+ in FosA is more complex.  It is probable, based on these 
results, that the binding of K+ is also responsible for structuring the K+-binding loop for 
the proper binding of GSH.  The structuring of the K+-binding loop is necessary for the 
proper orientation of K90 and R93 to bind GSH. 
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Figure 26: Activation of GSH by Y39 and Y128 with distances shown between the 
tyrosine hydroxyl groups, the GSH sulfhydryl, and the C1 position of fosfomycin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: Stereo view of GSH bound in Pa1129 showing the relationship between K+ 
binding and the position of K90 and R93.  The K+ ion is shown in orange. 
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CHAPTER IV 
 
RATIONAL DESIGN AND DNA RECOMBINATION IN THE EVOLUTION OF A 
BETTER FOSA FROM THE M. loti FOSX 
 
Results 
  
Enzyme Structure Overlay 
 The initial step in analyzing the evolutionary structural changes that may have 
taken place between the FosX and FosA enzymes was to create a structure overlay of two 
of these enzymes.  The most interesting FosX protein to use for this analysis was the one 
from Mesorhizobium loti.  The P. aeruginosa FosA and the M. loti FosX overlay very 
well with a mean RMSD = 0.9 Å (Figure 28). 
 
Rational Mutagenesis of the M. loti FosX 
 Once the structural alignment was complete, a search for differences in the active 
sites of the enzymes showed three specific amino acids to target.  These three amino 
acids in the FosX were E44, F46, and M57 (Figure 29).  The corresponding amino acids 
in the P. aeruginosa FosA are a glycine, tyrosine, and serine. Kerry Fillgrove made the 
point mutations in the M. loti FosX to the corresponding FosA residues in an iterative 
fashion.  Dr. Fillgrove discovered that the single mutation E44G was sufficient to 
completely abolish the hydrolase activity of the FosX.  The subsequent mutations were 
successful in increasing the GSH-transferase activity of the FosX enzyme.  The kcat for 
the M. loti FosX GSH transferase activity went from 0.15 ± 0.02 s-1 for the native enzyme 
to 5.0 ± 0.2 s-1 for the E44G/F46Y/M57S triple mutant. 
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Figure 28: Ribbon diagram of an overlay of the P. aeruginosa FosA, blue, and the M. 
loti FosX, green.  Mn is shown in purple, K in orange, and fosfomycin and GSH in stick 
form.  Used FosA structure with GSH modeled in and PDB 1R9C for FosX. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 29: Active site overlay of the P. aeruginosa FosA, blue, and M. loti FosX, green, 
depicting the three amino acid differences between the two enzymes.  GSH was removed 
to clarify the image. 
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 Many additional mutations were made in this triple mutant background.  These 
included the deletion of R99, V100, and E101, which shows up as an insertion in what is  
the K+-binding loop in FosA in multiple sequence alignments (Figure 30).  Additional 
K+-binding loop mutants included L89H, L91V, D92R, M93E, R94W, P95K, P98R, and 
R103D.  These mutations should have recapitulated the P. aeruginosa FosA K+-binding 
loop in the M. loti FosX.  Subsequently, residues T36, E37, F39, S40, C41, and S42 were 
deleted in a loop region that showed these residues to be an insertion when compared to 
the FosA enzymes in multiple sequence alignments (Figure 31).  The final mutations 
made were S34W/H/Q/N and R43Q to attempt to introduce GSH binding residues and 
D27G or R85Q in either the S34Q or S34N backgrounds to break a salt bridge formed in 
the FosX enzymes (Figure 32).  Unfortunately, every single mutation made after the 
initial triple mutation resulted in a decrease in activity.  No subsequent mutagenesis was 
ever able to rescue activity. 
Figure 30: Multiple sequence alignment of the FosA enzymes from P. aeruginosa and 
Tn2921 with the FosX enzymes from M. loti and L. monocytogenes.  Residues involved 
in GSH binding are colored red.  Residues involved in K+-ion binding are colored orange.  
A three amino acid insertion in the M. loti FosX K+-binding loop is colored blue. 
 
 
DNA Shuffling 
 Abandoning rational mutagenesis strategies, a DNA shuffling protocol was 
attempted., The DNA from two different Fos genes were shuffled and expressed in pET-
20 vectors.48 It is possible that at this point either an engineered mutant of FosXML was 
                87                                  102 
FosAP.a.         R E W K Q N R - - - S E G D S F Y F L 
FosAT.n.         T I W K Q N K - - - S E G A S F Y F L 
FosXM.l.         D M R P P R P R V E G E G R S I Y F Y 
FosXL.m.         E M K P E R P R V Q G E G R S I Y F Y 
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Figure 31: Ribbon diagram of an overlay of the P. aeruginosa FosA, blue, with the M. 
loti FosX, green, depicting one face of GSH binding.  A seven amino acid insertion in 
FosX is shown in black at the top right. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 32: Two views of the FosX salt bridge formed between D27 and R85.  The larger 
picture shows this from a similar vantage point as the overlay in Figure 26.  Inset is a 
detail view of the interaction between D27 and R85 (180º view from larger picture). 
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used or, at least, contaminated the PCR reactions.  The results of the three shuffling 
experiments resulted in the identification of six mutational variants (Table 2).  One of 
these variants was identified 10 times while the other five were only identified one time 
each.  The DNA analysis of these mutants showed that the most common variant has the 
same exact DNA sequence as an engineered mutant created by Lauren Beihoffer, with the 
exception of two single base mutations (Figure 33).  These single base mutations are 
responsible for the E60K and A63V mutations seen in all of the six mutant variants. 
 All of the mutants identified to date have had some variant of the active site triple 
mutant created by Kerry Fillgrove (unpublished).  Four of them have the exact same 
mutations, E44G/F46Y/M57S.  One mutant has two of the same three but has an E44S 
mutation and one has only one of the same mutations with E44S and M57L mutations.  
All six variants have the E60K and A63V mutations.  These are not the corresponding 
FosA residues but random mutants.  Five of the six mutants have the FosAPA K+-binding 
loop recapitulated.  A sequence alignment of the mutant strains against FosXML indicates 
the deletion of P96, G104, and R105 in this region, not the R99/V100/E101 deletion 
made in the rationally designed mutants.  One mutant has an S99P mutation in the K+-
binding loop (using mutant numbering).  A couple mutants also contained single point 
mutations that were not seen in any other variants.  One mutant has a T123M mutant and 
one has a E126K mutant. 
 Despite the potentially contaminated shuffling, three of the mutational variants 
were chosen to measure their kinetics and inhibitory capacity.  The three mutants chosen 
were shuffle mutants (DNAs) 1.1, 1.2 and 2.2.  Of these three, DNAs1.1 and 1.2 showed  
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Table 2: DNA recombinant mutants isolated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 33: Alignment of DNA shuffle mutant 2.2 with an engineered M. loti FosX 
mutant containing the E44G/F46Y/M57S triple mutant as well as the RVE K+-loop 
deletion and  R94W/P95K/P96Q/R97N/P98R/G102S/R105D. 
Gene Name K-loop Residues 94-103
1.1 E44S F46Y M57L E60K A63V WKQNRSEGDS(!P96, G104, R105)
1.2 E44G F46Y M57S E60K A63V T123M WKQNRSEGDS(!P96, G104, R105)
2.8 E44G F46Y M57S E60K A63V WKQNRPEGDS(!P96, G104, R105)
3.3 E44G F46Y M57S E60K A63V E126K WKQNRSEGDS(!P96, G104, R105)
3.4 E44S F46Y M57S E60K A63V WKQNRSEGDS(!P96, G104, R105)
WKQNRSEGDS(!P96, G104, R105)
2.2, 2.3, 2.4, 
2.6, 2.7, 2.9, 
2.10, 2.11, 
3.1, 3.2
E44G F46Y M57S E60K A63V
Triple Mutant Residues Other Residues
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Figure 34: A-C) Fosfomycin kinetics for DNAs1.1, 1.2, and 2.2.  D-F) GSH kinetics for 
DNAs1.1, 1.2, and 2.2. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 35: MIC plates for DNA shuffle mutants.  The number before "E" on each plate is 
the [fos] (µg/mL).  MIC values: for empty vector pET-20 (E), 10 µg/mL, for native M. 
loti FosX (L), 20 µg/mL, for the M. loti Triple mutant (LT), 20 µg/mL, for DNAs1.1 
(1.1), 60 µg/mL, for DNAs1.2 (1.2), >80 µg/mL, for DNAs2.2 (2.2), 10 µg/mL. 
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improved kinetics over the native FosXML and the triple mutant as well.  DNAs2.2 did 
not.  DNA 1.1 and 1.2 have a kcat/KMfos of 5 ± 1 x 104 and 1.2 ± 0.2 x 105 M-1s-1 
respectively.  However, their kcat/KMGSH was still very poor; only 6.4 ± 0.5 x 102 and 4.3 
± 0.2 x 102 M-1s-1 respectively.  Both mutants did have a much better MIC than native 
FosXML or the triple mutant; 60 µg/mL for DNAs1.1 and 120 µg/mL for DNAs1.2.  
Interestingly, despite only a few differences in amino acid sequence, DNAs2.2 had very 
poor kinetics (similar to native FosXML) and a worse MIC than even native M. loti FosX 
(Figures 34 and 35 and Table 3).   
 
Structure of DNAs2.2 
 The DNA shuffle mutant 2.2 was crystallized in microbatch trays under Al's Oil 
(a 1:1 v/v mix of silicon oil and paraffin oil) by microseeding.  The crystallization 
condition was a 1:1 mix of enzyme and buffer and crystals formed in 2-3 days.  A 
structure was solved to 2.0 Å using the native FosXML structure to solve the phasing 
using molecular replacement.  The overall structure is very similar to the native FosXML, 
which is not unexpected since the two enzymes are 87% identical.  The DNAs2.2 enzyme 
crystallized as a dimer in the asymmetric unit.  Interestingly, no metal ions were seen in 
the active site of the enzyme despite being present in a two fold molar excess in the 
crystallization conditions.  The only ligand apparent was a possible ammonium ion in one 
active site, but not the other. 
 The most interesting aspect of this structure is what should be the K+-binding 
loop.  In the DNAs2.2 mutant, this loop actually forms a β-strand and joins the β-sheet on 
the bottom half of the active site.  This leaves the active site very open.  It also kinks the 
c-terminal end of the loop 90º when compared to the K+-binding loop in the FosAPA 
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enzyme.  The position of the E60K and A63V mutations is also interesting.  These two 
residues are about 20 Å from the active site  and oriented towards the outside of the 
enzyme so it is not apparent what their function might be.  Still, these mutations are seen 
in all of the shuffle mutants.  
 
Table 3: Summary of Kinetic Data and MIC values for DNA shuffling mutants. 
 
Enzyme kcat/KM
fos M-1s-1 kcat/KM
GSH M-1s-1 MIC (mg/mL)
Pa1129 FosA 9.0 ± 1.4 x 105 4.1 ± 0.8 x 104 >20
M. loti FosX 5.0 ± 0.6 x 102 n.d. 0.02
KLF loti Trip. 8 ± 3 x 103 4.9 ± 0.2 x 102 0.02
Shuffle 1.1 5 ± 1 x 104 6.4 ± 0.5 x 102 0.06
Shuffle 1.2.3 1.2 ± 0.2 x 105 4.3 ± 0.2 x 102 0.16
Shuffle 2.2 9 ± 1 0.49 ± 0.03 0.01-0.02
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Discussion 
Enzyme Structure Overlay 
 The fosfomycin resistance enzymes are members of the VOC superfamily of 
enzymes, which include the extra-diol dioxygenases, bleomycin resistance protein, 
methylmalonyl-CoA epimerase, and glyoxalase 1.  While all of these proteins vary in 
their reaction mechanism, they are all structurally very similar.  All members of the VOC 
superfamily are homodimers that use a βαβββ motif to form a cup-shaped metal ion-
binding site.  Previous reviews of this superfamily have shown that despite their 
differences, the many members of this superfamily are basically super-imposable 
structurally.46 It is therefore not surprising that two more functionally related enzymes, 
such as the P. aeruginosa FosA and the M. loti FosX, are structurally very similar.   
 
Rational Mutagenesis of the M. loti FosX  
 The most interesting question in regards to the FosA/X enzymes is what small 
changes within their general structural scaffold leads to such a large disparity of function 
between the two enzymes.  The work done on the functional analysis of several different 
mutants has helped to answer this question, in part. 
 There are only three different amino acids in and around the active site of the 
FosA and FosX enzymes.  These three amino acids, E44, F46, and M57 in the M. loti 
FosX, were mutated to their FosA equivalents, glycine, tyrosine, and serine.  It was found 
that the single E44G mutation was sufficient to completely abolish the FosX activity of 
the M. loti enzyme.  The crystal structure of the M. loti FosX suggests that this residue is 
properly positioned to activate water for addition to the C1 position of the antibiotic.43 
The other two residues serve to increase the turnover of the FosA reaction catalyzed by 
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the M. loti enzyme.  The F46Y mutation introduces the tyrosine residue responsible for 
ionizing GSH for addition to fosfomycin in the FosA enzyme and M57S introduces a 
putative GSH binding residue.55 Also, the smaller serine residue opens up space for GSH 
binding.  An overlay of the M. loti FosX with the P. aeruginosa FosA with GSH modeled 
in suggests that M57 would sterically hinder the binding of GSH. 
 This original triple mutation, made by Kerry Fillgrove, was the first step in 
engineering a better FosA enzyme from the M. loti FosX scaffold.  This initial mutation 
was a good first step, increasing estimated kcat 30 fold to a marginally respectable 5.0 s-1.  
However, it was also shown that as more and more GSH is added to the reaction the 
turnover rate continues to increase, indicating that this enzyme is not saturating with 
respect to GSH.  The next step in developing a better FosA activity was to engineer a 
better GSH binding site. 
 The first step in creating a better binding site was trying to create a K+ binding 
loop.  This may sound like a very roundabout method, but recall from Chapter 3 that two 
of the GSH binding residues, K90 and R93, are located on the K+-binding loop.  The loss 
of the enzymes ability to be activated by potassium, presumably by no longer binding it 
properly, as evidenced by the K+-loop mutant made in the P. aeruginosa FosA, results in 
poor activity similar to the single point mutations of K90 and R93 to alanine.  Introducing 
proper K+-binding and activation in the M. loti FosX should result in proper GSH 
binding.  Therefore, the subsequent introduction of the corresponding K90 and R93 
residues from FosA should be able to be inserted into the FosX and create a GSH binding 
site. 
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 A multiple sequence alignment of several FosA and FosX enzymes shows that 
there is a three amino acid insertion in the K+-binding loop in the FosX enzymes.  The 
first task in engineering a proper K+-binding loop in FosX was to eliminate the three 
amino acid insertion.  In the M. loti FosX, these residues were R99, V100, and E101.  
Unfortunately, the deletion of these residues in the triple mutant background not only did 
not introduce any K+ activation, but actually demonstrated a decrease in turnover as 
compared to the active site triple mutant alone.  We decided, therefore, to completely 
replace the FosX loop with the corresponding residues from the FosA enzyme so that the 
M. loti FosX would have the entire P. aeruginosa FosA K+-binding loop reconstituted in 
the triple mutant background.  These mutations did not lead to any increase in activity 
and remained less active than the triple mutant alone. 
 The other end of GSH, the glycine carboxylate, is bound to FosA by hydrogen 
bonding interactions with W34 and Q36.  In the P. aeruginosa FosA these two residues 
protrude from a turn between two β2 and β3 of the first βαβββ motif.  According to 
multiple sequence alignments, there is a seven amino acid insertion in this region in the 
FosX enzymes.  The deletion of this insertion and the mutation of appropriate residues to 
the corresponding tryptophan and glutamine residues in the background of the triple 
mutation plus the K+-binding loop results in an even further reduction in activity in the 
enzyme. 
 The deletion and mutation of these loops in the enzyme resulted in decreased 
functionality.  For this reason the attempt to rationally design a better FosA enzyme from 
the M. loti FosX was abandoned.  Instead a different approach was tried – DNA 
shuffling. 
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DNA Shuffling 
 In theory, DNA shuffling is able to take to similar genes and shuffle the genetic 
material to create a library of new genes with varying function.48 This process works 
better the more similarity there is in the sequence as this aids in gene overlap.  The P. 
aeruginosa FosA and M. loti FosX are only about 48% identical, severely limiting the 
potential number of overlaps possible.  Still, from three different shuffling experiments 
six different mutant variants were isolated.  However, subsequent analysis seemed to 
indicate that there was not much, if any, real overlap of any length of the two gene 
products.  Subsequent analysis seems to indicate that either the FosX gene used was not 
the native FosX but an engineered mutant that had the triple mutant, the RVE deletion, as 
well as seven other point mutations in the K+-loop region.  It is possible that this gene 
was just contaminating the PCR reactions, but the exact nature of the contamination 
introduction is not known. 
 All of the mutants isolated to date are genetically identical to the engineered FosX 
enzyme with only a few single base pair mutations.  These single mutations are 
responsible for the variation among the shuffle results.  The DNA shuffling procedure is 
known to introduce random mutations in numbers similar to error prone PCR.48 All of the 
mutants isolated had some version of the active site triple mutation.  The variation seen 
among the mutants was due to single base mutations, which were a result of the shuffling 
procedure, not from an actual shuffling event.  All of the mutants have the designed K+-
binding loop with the exception of one, which again has a single base mutation that 
changes a serine to a proline in the middle of the loop. 
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 There are several new mutations that are introduced, but these are also the result 
of single base mutations.  It is unclear why every single mutant isolated contains both the 
E60K and A63V mutations.  These two residues are located about 20 Å from the active 
site of the enzyme and do not seem to add any function that can be tested kinetically.  
Still, their presence in every mutant does seem to suggest some selective advantage.  The 
other two new mutations were only seen once each and both are near the C-terminus of 
the enzyme and wouldn't seem to be involved in the proper functioning of the enzyme. 
 Only three of the six mutants have been functionally characterized and two of the 
three show markedly increased activity as compared to the native M. loti FosX.  The third 
mutant, DNAs2.2, however, is almost non-functional as an enzyme and has an even 
worse MIC than the native FosX.  However, there are only a few amino acid differences 
between this mostly inactive mutant and the two more active mutants, DNAs1.1 and 1.2.  
DNAs1.1 and 2.2 only differ in the triple mutant residues with 2.2 having the same 
mutations as those originally created by Kerry Fillgrove and 1.1 having instead E44S and 
M57L mutations.  The only difference between DNAs1.2 and 2.2 is the T123M mutation 
at the C-terminus.  It is not clear at this time why these few mutations institute such a big 
difference in activity.  Structural studies of these enzymes, however, could prove 
invaluable in discerning the nature of these relationships. 
 
Structure of DNAs2.2 
 The crystal structure of DNAs2.2 is interesting (Figure 36).  Overall, this structure 
aligns very well with the native FosX enzyme as well as the P. aeruginosa FosA.  The 
one major structural difference, however, is a rather substantial one.  In DNAs2.2 the K+-
binding loop actually forms a β-strand and joins the β-sheet surrounding the active site.  
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This opens up the active site, but it also prevents the binding of either K+ or GSH.  There 
is a small loop formed by three residues, but it is more of a β-turn instead of a loop.  Even 
so, an overlay of DNAs2.2 and the P. aeruginosa FosA shows that this small turn is 
oriented 90º from the FosA K+-binding loop (Figure 37). 
 What this structure really does is explain why our attempts to engineer a better 
FosA from the M. loti FosX were unsuccessful.  The very first deletion event, that of the 
RVE residues from the K+-binding loop, resulted in the proper shortening of that loop to 
form the β-strand seen in the crystal structure.  Every mutation made from that point on 
only served to modify an already drastically changed loop.  There is no way to introduce 
K+-binding to this system and the GSH binding residues are not in the proper location.   
 This structure does not answer the question of why this enzyme is not active as 
compared to the DNAs1.1 and 1.2 mutants.  In fact, the DNAs2.2 crystal structure did not 
have any density past T122, just missing out on the T123M mutation seen in DNAs1.2.  
Still, this region is not very close to the active site so an apparent benefit from this single 
mutation is not evident.  Hopefully the structures of DNAs1.1 and 1.2 can be solved for 
better comparative analysis. 
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Figure 36: Ribbon diagram of DNAs2.2.  The enzyme crystallized to 2.0 Å as a dimer in 
the asymmetrical subunit.  Also shown above is ammonia from the crystal buffer, in blue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37: Ribbon diagram of an overlay of the P. aeruginosa, FosA in blue, M. loti 
FosX, in green, and DNA s2.2 in red.  Mn2+ is shown in purple, K+ in orange, and the 
ammonium ion is shown in bright blue. 
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CHAPTER V 
 
DEVELOPMENT OF HIGH-THROUGHPUT SCREENS FOR THE DISCOVERY OF 
BIOACTIVE INHIBITORS TO FOSA FROM P. aeruginosa 
 
Results 
 
 Monobromobimane (mBBr) has been used for many years as a selective 
fluorescent tag for thiol compounds.68-70 These applications were mostly focused on 
HPLC based discovery and separation of these compounds.  In this project, a new spin 
was put on this old bit of technology. 
 To test the reaction of mBBr and GSH in a FosA reaction system, 2 mL reactions 
were run on a fluorimeter to check the mBBr signal in the reaction buffer system.  The 
compound mBBr has very little intrinsic fluorescence, but the GS-mB product is highly 
fluorescent.  The product fluorescence can be easily measured with λex = 370 nm and λem 
= 480 nm (Figure 38).  These first experiments showed that there was a definite 
difference in the fluorescence intensity between reactions with and without enzyme or 
GSH and indicated that this might be a viable method to use in creating an HTS assay 
(Figure 39). 
 
Assay Development 
 The first two versions of this assay were developed using the known FosA 
inhibitor phosphonoformate, Ki = 0.4 ± 0.1 µM.49 As a known entity, phosphonoformate 
(Pf) was a good candidate from which to create an assay since it would make a good 
standard from which to proceed.  The first step was to measure a concentration-response 
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Figure 38: Reaction of GSH with mBBr to form the fluorescent covalent product. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 39: Initial test of mBBr reaction: 200 nM Pa1129, 50 µM Mn2+, 100 mM K+, 750 
µM fosfomycin, 500 µM GSH, 60 min reaction time.  Add 1 mM mBBr and let reaction 
run for 30 min.  Red line adds 1 mM Pf to reaction mixture. 
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curve (CRC) for Pf in this assay system.  A final concentration of 8 mM was selected as a 
starting point and a 3x serial dilution was made in the reaction buffer.  The reactions were 
run in solid black 384-well microplates.  This initial experiment showed that 
phosphonoformate did indeed inhibit FosA under these conditions.  The data was 
averaged and fit to a sigmoidal dose-response curve using GraphPad Prism.  An IC50 = 60 
µM and an IC80 = 200 µM were calculated for Pf. 
 The assay was re-tooled after the first minor screen to increase efficacy.  The Pf 
control IC50 for this second version of the assay was 19 µM and the IC80 was 72 µM 
(Figure 40).  For reasons that will be discussed later, Pf was later replaced with a ZnCl2 
solution in DMSO.  Zinc has an IC50 = 158 ± 4 nM in this assay and completely inhibits 
the reaction at a concentration of 5 µM (Figure 40).  A zinc concentration of 5 µM was 
used to completely inhibit the reaction as the control in the screens. 
 
Z’ Calculations 
 The best way to establish whether or not an assay is valid for a HTS format is to 
calculate the Z' for that assay.60 This was performed for Pf before running any unknown 
compounds to determine HTS viability of the assay.  Full plate Z' values were calculated 
for both IC50 and IC80 concentrations of Pf by setting up a full plate checkerboard of Pf 
against a DMSO control.  The Z' for each concentration of Pf was calculated to be 0.76 
and 0.85, respectively.  The Z' values using the second version of the assay for Pf were 
both calculated to be 0.78 (Figure 41).  A Z' > 0.5 indicates that an assay is able to 
successfully discriminate between partially inhibited and uninhibited populations of 
enzyme and is viable for high-throughput screening. 
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Figure 40: Concentration-Response Curves for phosphonoformate in the second version 
of the assay and for ZnCl2 in the final version of the assay.  All data in quadruplicate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 41: Full plate Z' calculations for phosphonoformate in the second version of the 
assay and for ZnCl2 in the final version of the assay.  The blue triangles are the positive 
control, either Pf or Zn, and the red squares are the negative controls, DMSO.  The dotted 
lines indicate three standard deviations above and below the mean for each population. 
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 A concentration of 5 µM Zn gives a Z' = 0.7 (Figure 41).  All of these results 
indicate a viable HTS assay, which is adequately able to resolve inhibited and uninhibited 
reactions. 
 
Compound Screens 
 A small screen (3200 compounds) was performed using the Pf standard assay to 
estimate an initial hit rate.  Hits were defined as compounds that gave a signal greater 
than three standard deviations above the mean for all compounds tested on a single plate.  
The fluorescence reading of each plate was measured both before and after the addition 
of mBBr in order to eliminate any false positives that would result from the intrinsic 
fluorescence of the compounds being tested.  Using this strategy, a total of 104 hits were 
identified, a hit rate of 3.25% (Figure 42). 
 When the same compound screen was repeated using the second version of the 
assay the method of picking hits was modified.  Instead of picking hits on a per-plate 
basis, hits were picked based on the whole population of compounds screened on that 
day.  The raw data was normalized to a % of the maximum value for the positive controls 
on each plate and then the percentages for all 3200 compounds were used to determine 
the average and standard deviation.  Hits were identified as compounds that gave a % 
max signal greater than three standard deviations above the mean for all compounds 
screened.  This reduced the number of hits from 104 to just two, a hit rate of 0.063% 
(Figure 43).   
 The third, and final, version of this screen changed the standard to ZnCl2 in 
DMSO, but all other factors remained constant.  In this final version of the assay four hits  
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Figure 42: Hits from the first compound screen.  Hits were picked by identifying 
compounds with a greater than 3σ deviation above the mean for all compounds on a 
single plate.  The multiple colors depicted above illustrate an attempt to create a 
hierarchy of inhibitory capacity among these compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 43: Full data set analysis from the second compound screen.  The Z' for the 
controls over the whole data set was only 0.43.  The compound average was 12.4 with a 
standard deviation of 2.6.  The positive control, Pf, is in blue, the negative control, 
DMSO, is in green, the compounds are in red and the grey line designates the hit cutoff, 
here at 20.3.  Hits are compounds above this cutoff line. 
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Figure 44: Full data set analysis for two zinc controlled assays.  For the 3200 compound 
assay the control Z' was 0.77.  The average for the compounds was 9.5 was a standard 
deviation of 1.7.  The 3s cutoff was 14.4.  For the 1600 compound screen the control Z' 
was 0.66.  The compound average was 13.4 with a standard deviation of 2.0.  The 3s 
cutoff was 19.4. The positive control, Pf, is in blue, the negative control, DMSO, is in 
green, the compounds are in red and the grey line designates the hit cutoff.  Hits are 
compounds above this cutoff line. 
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were recorded, a hit rate of 0.125%.  A subsequent assay of 1600 compounds netted five 
more hits, a rate of 0.3125% (Figure 44). 
 
Hit Confirmation 
 The hits from the first version of the screen were confirmed by ordering new 
compounds from ChemBridge and making new 10 mM stocks in DMSO.  The assay was 
repeated in the exact same manner.  One compound, CB 5838696 was no longer available 
from ChemBridge so four structurally similar analogs were ordered for the confirmation 
experiments.  These compounds, CB 5844324, 5848410, 5846450, and 5838937, were 
the only compounds to show any activity in the confirmation screen.  This gives an 
effective confirmation rate of only 0.96%, only one compound out of 104. 
 The confirmation screen was also performed in the absence of GSH to make sure 
that the signal wasn't coming from any compound reaction with mBBr.  No reaction was 
seen to indicate that this would be a problem with these compounds. 
 Since the second and third versions of the assay resulted in significantly fewer 
hits, the method of confirmation was changed to a CRC profile assay.  The fewer number 
of compounds made this type of assay more viable.  Both of the hits from the second 
version of the assay, CB 5838696 and CB 5155620, were confirmed in this manner.  This 
gives a confirmation rate of 100%. 
 All four of the hits from the 3200 compound screen from the third version of the 
assay were confirmed.  These hits were the same as for the second version of the assay as 
well as compounds CB 5155500 and CB 5841758.  Of the five hits from the subsequent 
1600 compound screen, only four could be screened in the confirmation assay.  One 
compound ID could not be identified.  Of the four that could be screened, two 
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compounds were confirmed as active.  These were compounds CB 6106988 and CD 
1597-0070.  Compounds CD 1605-0089 and CD 6031-1896 were not confirmed.  This 
gives confirmation rates of 100% for the 3200 compound screen and 50% for the 1600 
compound screen, an overall confirmation rate of 75%. 
 
CRC for Confirmed Hits 
 The derivatives of CB 5838696 were tested for their concentration-response 
profiles.  All of the compounds were screened on a single plate to limit plate-to-plate 
variation.  For the four derivatives of CB 5838696 tested, CB 5844324, 5848410, 
5846450, and 5838937, IC50 values of 470 ± 10, 690 ± 10, 960 ± 20, and 1300 ± 200 nM 
were calculated.  This is 20-60 times lower than the model inhibitor, phosphonoformate, 
which has an IC50 = 17.8 ± 0.1 µM.  The other confirmed hits have much higher IC50 
values.  In order of efficacy: CB 5155500 = 15.1 ± 0.3 µM, CB 5847158 = 17.9 ± 0.4 
µM, CD 1597-0070 = 28.8 ± 0.6 µM, and CB 6106988 = 74 ± 1 µM (Figure 45).  An 
IC50 could not be calculated for CB 5155620 due to solubility issues. 
 
Compound Synthesis and Activity 
 Compound CB 5838696 and its four analogs were independently synthesized by 
the Vanderbilt Chemical Synthesis Core (VCSC) as they became less commercially 
available.  The synthetic methods were not available from ChemBridge, so it was not 
possible to follow the exact method.  The method used can be found in Figure 16.  The 
compounds from the VCSC were determined to be structurally identical to the 
ChemBridge compounds based on 1H, COSY, HSQC, HMBC, and selective NOESY 
NMR, see Appendix.  The kk-5-series of compounds showed no activity against FosA.  
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Figure 45: Concentration-Response Curves for hit compounds from the various screens. 
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 The kk-8-series of compounds, however, showed comparable inhibition of FosA as their 
commercially purchased counterparts. 
 To check for potential impurities in various compounds, both the CB 5846450 
and its corresponding VCSC compound were further purified by HPLC.  Single peaks 
were seen in the HPLC traces for both compounds indicating the lack of any potential 
organic impurities.  The HPLC purification did not change the activity of the kk-5-series 
compound; it was still inactive.  However, the ChemBridge compound lost all activity 
after HPLC purification (Figure 46). 
 The only explanation for this loss of activity seems to be the presence of an 
inorganic impurity.  The only synthetic information ChemBridge could supply was that 
their compounds were synthesized solvent free with ZnCl2.  The presence of high 
concentrations of zinc would not affect the NMR spectra or show up in the HPLC profile.  
It could, however, potentially inhibit the FosA metalloenzyme.  Indeed, when 
stoichoimetric amounts of zinc are added to an HPLC purified ChemBridge compound, 
its inhibitory activity is restored (Figure 47). 
 The kk-8-series of compounds constitute the independent synthesis of four of the 
five other hits found via HTS screening.  These compounds showed similar activity to 
their commercially purchased counterparts.  The one compound not synthesized, CB 
5155620, was not re-synthesized because an IC50 couldn't be calculated for this 
compound due to solubility issues. 
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Figure 46: HPLC Purification of CB 5846450 results in a near total loss of inhibitory 
capacity. ChemBridge has only been able to divulge that the chemist they purchased 
these compounds from made them using a solvent free method with ZnCl2.  ZnCl2 has 
been shown to inhibit FosXL.m. (IC50 = 3 µM, see Chapter 6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 47: Single experiment demonstrating that Zn is most likely responsible for 
compound activity.  HPLC purification renders the compound inactive but the addition of 
stoichiometric zinc restores activity in a manner similar to pure Zn2+. 
O
N
N
O
N
S
F
O
IC50 = 1.31 ± 0.03 µM 
CB Comps 
IC50 = NA 
HPLC Purify 
HPLC 
+ stoichiometric Zn2+ 
Compare 
IC50 = 117 ± 3 nM 
IC50 = 158 ± 4 nM IC50 = 154 ± 4 nM 
 91 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 48: A) Cartoon depiction of the technique of NAA, taken from ref. 63.  B) NAA 
analysis of compounds CB 5839909 and 5992599 showed heavy zinc contamination in 
the dry powder.  Re-calculating the CRC for these compounds knowing the zinc 
concentrations gives IC50 values very similar to zinc alone. 
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Zn Analysis by Neutron Activation 
 None of the five ChemBridge compounds tested were available to send for zinc 
analysis; so two other analogs were purchased.  These two compounds, CB 5839909 and  
CB 5992599, were sent to Elemental Analysis, Inc. in Lexington, KY for testing by 
Neutron Activation Analysis (NAA).  NAA works by measuring the element specific 
radioactive decay of a target element.  The emitted gamma rays are elementally specific 
in their half-life and energy.  The amount of a target element in a sample can also be 
determined based on the intensity of the gamma ray emission. The amount of zinc present 
was determined to be 6.8 ± 0.4% and 10.0 ± 0.4% of the dry weight for compounds CB 
5839909 and CB 5992599, respectively.  Re-analyzing the CRC data for these two 
compounds using the known concentrations of zinc changes the IC50 for CB 5839909 
from 1.15 ± 0.02 µM to 440 ± 10 nM and the IC50 for CB 5992599 from 1.88 ± 0.05 µM 
to 620 ± 20 nM (Figure 48).  The IC50 for pure Zn is 158 ± 4 nM.  No detectable zinc was 
seen for compounds CB 6106988, 5847158, and 7433453 (an active derivative of CB 
5155500 and 5155620). 
 
 
 
 
 
 
 
 
Figure 49: Concentration-Response Curve for Zn in the HPLC assay. 
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HPLC Assay 
 The same HPLC based assay system used for FosA kinetics can also be used for 
inhibitor analysis.58 Using the exact same reaction conditions but with the kinetic assay 
quench and derivatization the amount of fos-GSH product can be measured directly.  
Using Zn as an inhibitor an IC50 = 24 ± 2 µM can be measured directly (Figure 49). 
 
 Resazurin Bioactivity Assay 
 It is possible to grow liquid culture of E. coli in 96-well plates and monitor the 
growth of the cells using the color change dye Resazurin (Figure 50).57 In checkerboard 
tests, using kanamycin as a positive control, Z' values of 0.75 can be achieved in as little 
as six hours, indicating a robust difference in the fluorescence of the dye between wells 
with and without growth.  When stretched out to 24 hrs., Z' values of 0.85 are observed. 
The liquid cultures were grown using LB media with 100 µg/mL ampicillin and 500 µM 
glucose-6-phosphate (G6P).  The FosA gene was expressed in a pET-20b vector with a 
leaky promoter.  The vector contributes ampicillin resistance and the G6P aids in the 
uptake of fosfomycin by activating phosphate transport systems.28 The plate set-up is a 
slightly modified version of the one used by Sarker et al. (Figure 51).57 This set up makes 
possible the testing of several different serial dilutions of compounds in each plate.  
 
 
 
 
 
 
 
 
Figure 50: Resazurin is reduced by living bacteria to resofurin.  This imparts both a color 
change, from dark blue to bright pink, but also a fluorescent change that can be 
monitored with λex = 530 nm and λem = 590 nm. 
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Figure 51:  96-well plate set-up for the resazurin assay.  The sterile control contains no 
bacteria and the negative control does have bacteria but no compounds. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 52:  Resazurin growth curves for the four analogs of the hit compound CB 
5838696 over a 12-hour period.  The numbers in the legends of A and C are 
concentrations in micromolar while those in B and D are in nanomolar.   
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 The four derivatives of CB 5838696 all have very low solubility in LB medium, 
about 50 µM.  At higher concentrations, around 3 mM some growth slow down can be 
observed (Figure 52).  At these concentrations, however, there is a lot of precipitate 
compound and it is very likely that the slight activity noted is most likely due to the 
heavy zinc contamination of the compounds. 
 When the confirmed hits from the Zn-controlled screens were tested for their 
bioactivity, four compounds were found to show a concentration-dependent effect on 
growth rates of E. coli transformed with the Pa1129 FosA (Figure 53).  All four of these 
also showed effects on the growth rates of E. coli transformed with an empty pET-20 
vector as well (Figure 54).  Compounds CB 5155500, CB 6882791, and CB 7226895 
demonstrate a decrease in growth at around 400 µM while compound kk-8-054 (same as 
CB 6106988) shows a decrease in growth at 100 µM.  Millimolar concentrations of all 
four compounds are able to almost slow growth completely.  The trends are not as easy to 
spot in the empty pET vector cells, but all four compounds do show a decrease in growth 
rates as well. 
 Several of the compounds tested are able to inhibit bacterial growth even after 24 
hours of incubation at 37 ºC (Figure 55).  Compound CB 7226895 does not completely 
inhibit the growth of transformed E. coli, either with or without FosA.  Compounds CB 
5155500, CB 6882791, and kk-8-054 all have the ability to deter the growth of E. coli 
transformed with the Pa1129 FosA.  At concentrations of 780 µM, both CB 5155500 and 
CB 6882791 are able to inhibit the long-term growth of E. coli transformed with Pa1129 
FosA (Figure 56).  However, no long-term effect is seen in the growth of E. coli 
transformed with empty pET-20, except at very high, 6 mM, concentrations of CB 
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5155500.  At a concentration of 195 µM, compound kk-8-054 demonstrates a long-term 
effect on the growth of E. coli with and without the FosA enzyme (Figure 56). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 53: Growth curves for E. coli transformed with a pET-20 vector containing the 
Pa1129 FosA.  The numbers in the legend for each chart is the concentration of inhibitor 
in micromolar. A) CB 5155500.  B) CB 6882791.  C) CB 7226895.  D) KK-8-054. 
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Figure 54: Growth curves for E. coli transformed with an empty pET-20 vector.  The 
numbers in the legend for each chart is the concentration of inhibitor in micromolar. A) 
CB 5155500.  B) CB 6882791.  C) CB 7226895.  D) KK-8-054. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55: 96-well plates with E. coli grown over 24 hr. in the presence of resazurin.  
The dark blue wells are where no cell growth occurred.  The red wells are where cell 
growth did occur.  A) Cells with the Pa1129 FosA and compound CB 5155500, 6882791, 
7226859, and 6107397 in rows C-F.  B) Cells with empty pET-20 and compound CB 
5155500, 6882791, 7226859, and 6107397 in rows C-F.  C) Cells with the Pa1129 FosA 
and compound kk-8-054, kk-8-056, kk-8-058, and kk-8-060 in rows C-F.  D) Cells with 
empty pET-20 and compound kk-8-054, kk-8-056, kk-8-058, and kk-8-060 in rows C-F. 
A. B. 
C. D. 
A B 
C D 
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Figure 56: Comparison of the Fl. 590 nm for the Pa1129 FosA and empty pET-20 cells 
after 24 hr. of incubation at 37 ºC.  A) CB 5155500.  B) CB 6882791.  C) KK-8-054. 
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Discussion 
 This assay is designed to be a quick assay to screen for inhibitors specific to the 
FosA enzyme (Figure 57).  The assay, as developed, demonstrates good sensitivity and 
has a theoretically small chance of false negative results.  Using glutathione as the 
limiting reagent at a 50x molar concentration to the compounds being tested ensures that, 
even should any compounds in the screen bind with GSH, the reaction will still run.  Any 
compounds that react with GSH would probably not be good drug candidates, so the loss 
of these compounds is minimal.   
 This assay system is easily corrected for any false positive results that would 
occur due to the inherent fluorescence of the compounds in the library by simply taking 
plate readings both before and after the addition of the fluorophore.  Also, should any 
compounds react with the fluorophore, a secondary reaction run in the absence of GSH 
can confirm whether any signal produced by the reaction is due to genuine inhibition of 
the FosA reaction. 
 
 
Figure 57: Cartoon depiction of the FosA assay.  A) With no inhibitor present all GSH is 
tied up as product.  The addition of mBBr will then give no fluorescent signal.  B) If an 
inhibitor is present, the formation of product will be hindered leaving a pool of GSH to 
react with the mBBr when added, yielding the fluorescent GS-mB product. 
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 This assay has undergone several method changes to get to one that works 
properly.  The first version of this assay identified 104 hits out of 3200 compounds 
screened.  However, the confirmation screen only confirmed one hit out of those 104 and 
that one confirmation was actually four analogs of a compound no longer commercially 
available, CB 5838696.  In essence, this gives a confirmation rate of less than 1% for this 
assay.  A very generous threshold for confirmation would be about 50%, so this version 
of the assay proved to be extremely error prone. 
 Several steps in the assay were changed around and some were eliminated to 
create the second version.  The number of hits identified dropped to only two compounds 
when using the exact same 3200 compounds as the first screen.  Both of these were 
confirmed, a 100% confirmation rate.  The lower number of false positives was due to 
three major changes.  One was the method of hit picking – switching to the population 
analysis.  A population analysis distributes error over the entire population of compounds 
and removes any plate-to-plate variability.  Two other changes were also instrumental in 
the success of this second version of the Pf controlled assay. 
 The fewer number of liquid handling steps in the second version of the Pf 
controlled assay helped to reduce the overall error as less compound and enzyme 
manipulation is required.  The more significant changes, however, most likely had to do 
with changing from polystyrene to polypropylene plates and using methanol instead of 
acetonitrile for the mBBr.  According to the chemical stability information on the Greiner 
Bio-One website, PS plates are very unstable in AcCN.  The plates used in the first 
version of the assay were holding a solution of 17% AcCN for 30 min, which could lead 
to severe scoring of the plates as the PS starts to dissolve.  Polypropylene plates are also 
 101 
unstable in AcCN, so a different mBBr solvent was needed.  Monobromobimane is really 
only soluble in AcCN, DMSO, and methanol for the purposes of this assay.  DMSO 
forms a complex with mBBr slowly over time, so storage in DMSO is not possible.  
Polypropylene plates are, however, stable in methanol, so this combination of plate type 
and solvent was used for the second version of the assay.  This should reduce any error 
that would come from the chemical instability of the plates and solvents.  The results 
from the second version of the assay were highly satisfactory. 
 The only drawback to this version of the assay was the continued necessity of 
adding Pf manually as the positive control.  The manual addition of controls slows down 
the overall process and creates a situation where the controls do not act as process 
controls since they do not undergo the same liquid handling steps.  Since Pf is not soluble 
in DMSO, it cannot be added to the reaction plates using the Labcyte Echo.  This makes 
Pf a less than ideal positive control for this assay.  However, as will be discussed later, 
the presence of high concentrations of zinc in some of the confirmed hits allowed for the 
creation of a final assay that eliminates this concern. 
 Zinc chloride is soluble in DMSO and can, therefore, be used as a positive control 
for this assay.  Zinc is a much better inhibitor of FosA than Pf is, so less compound needs 
to be used.  Zinc is also much cheaper than Pf, which lowers the operating cost for a 
large-scale screen.  Adding the controls with the Echo speeds up the assay process and 
gives a much tighter distribution of fluorescence for the entire population of controls over 
the course of a screen.  A comparison of the overall Z' for the second version of the Pf 
controlled assay and the zinc controlled assay shows that the Zn controlled assay is much 
more able to differentiate inhibited and uninhibited reactions.  In fact the Z' for the Pf 
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assay was only 0.43 due to a large standard deviation in the positive controls.  The Z' for 
the Zn screen was 0.77. 
 The zinc assay uses a higher than IC50 concentration to completely inhibit the 
reaction.  This is done so that all data points from the compounds being screened will be 
within the boundaries of the controls.  This was not the case in the second version of the 
Pf controlled screen where one compound was a much better inhibitor and fell outside of 
the control boundaries.  Using zinc creates more space between the positive and negative 
controls and actually helped to identify more confirmed hits when screening the same 
3200 compounds.  The zinc version of the assay has found, to date, nine hits out of 4800 
compounds, six of which were confirmed, and one that was not able to be identified. 
 Only getting six confirmed hits out of 4800 compounds, a 0.167% hit rate, may 
seem relatively low.  However, when the entire Vanderbilt Collection of compounds is 
screened, containing around 160,000 compounds, we should expect to get around 267 
hits.  While only around 200 or so of these may be confirmed, this would be a more than 
sufficient start in the search for new inhibitors.  The best compounds could then be 
selected for modification from a medicinal chemistry approach to develop more potent 
and bioactive inhibitors to FosA. 
 
Confirmed Hits 
 The compounds that were confirmed as hits were subjected to more testing 
to ascertain their IC50 values and to authenticate their ability to inhibit FosA.  Many of 
the compounds tested have IC50 values much smaller than the model compound Pf, while 
others are about as potent and others are less so (Figure 58).  All of this is to be expected 
from a properly functioning screen. 
 103 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 58:  All hits from the compound screens with the plate ID and well number from 
the Vanderbilt Collection, the ChemBridge or ChemDiv ID number and IC50 values. 
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 Most of the secondary work to date has focused on CB 5838696 and its analogs 
since these compounds have a much lower IC50 than any of the others identified (Figure 
59).  The initial IC50 and Kd data for these compounds seemed to indicate that a structural 
scaffold had been found with excellent inhibitory capacity and very tight binding to FosA 
(all compound Kd values were lower than the native substrates fosfomycin and GSH).  
However, once these compounds were independently synthesized by the VCSC, they 
showed no activity against FosA. 
Based on the limited information available from ChemBridge in regards to the 
synthesis of their compounds, it was proposed that the ChemBridge compounds were 
contaminated with zinc.  Zinc is able to inhibit the closely related FosX enzyme from 
Listeria monocytogenes (Brown and Armstrong, unpublished), so it was hypothesized 
that it could also inhibit the FosA enzyme from P. aeruginosa.   
To determine whether or not zinc might be present in the ChemBridge samples 
we further purified them by HPLC and re-ran the HTS assay.  This purification led to the 
almost complete loss of activity by the compounds.  A stoichiometric concentration of 
zinc was then added back to one compound, CB 5846450.  This restored the purified 
compounds activity against FosA.  In addition, the IC50 calculated for this solution was 
identical to pure zinc, within error.  All of which pointed to zinc contamination being the 
reason for the activity seen in this family of compounds and would help explain why they 
all have very similar IC50 values despite the differences in their structures. 
To determine the exact amount of zinc in these compounds, two were sent to 
Elemental Analysis, Inc. for zinc concentration determination.  Elemental Analysis, Inc. 
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Figure 59: All derivations of CB 5838696 tested.  All compound IDs beginning with CB 
were ordered from ChemBridge.  The compound IDs beginning with VU were 
synthesized by the Vanderbilt Chemical Synthesis Core. 
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(Lexington, KY) used a technique called Neutron Activation Analysis (NAA) to 
determine the % zinc in the dry weight of compounds CB 5839909 and CB 5992599.  
This analysis irradiates the sample and then monitors the radioactive decay.  Each 
element has a specific wavelength of decay and can be identified thusly.  The amount of a 
specific element can then be quantitated by measuring the intensity of the gamma waves 
being emitted.62 NAA analysis on CB 5839909 and CB 5992599 showed that a 
significant percentage of the dry weight of the compound was actually zinc.  In fact, 
using these known concentrations and back calculating the IC50 for the zinc in the 
sample, an IC50 for both compounds was calculated that was very near the IC50 of zinc 
alone.  This would suggest that the inhibitory ability of these compounds stems from their 
high zinc contamination and not from the compounds themselves.  This also suggests that 
the differences seen for the IC50 values among the compounds is most likely due to the 
amount of zinc present, not from any structural differences between the compounds. 
The final step was then to confirm that zinc could actually inhibit the FosA 
enzyme using another assay besides the HTS assay.  This was done using the same HPLC 
based assay used in kinetics measurements of FosA because it directly measures the 
amount of product being formed.  This analysis showed that zinc could indeed inhibit 
FosA, but at a much higher IC50 than the HTS assay suggests.  It is not clear at this time 
why this discrepancy may exist since the conditions for both assays were identical aside 
from the quenching of enzymatic activity.  However, it does offer conclusive evidence 
that Zn2+ is able to inhibit FosA and is the likely culprit in the activity noted for CB 
5838696 and its analogs. 
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The other five confirmed hits have not been as extensively tested since so much 
focus was placed on CB 5838696 and its analogs.  These compounds have been 
synthesized by the VCSC and shown to exhibit similar activity to the commercial 
purchased compounds.  The lack of zinc in these samples and the difference in structure 
among these hits is interesting, but all of these compounds are relatively poor inhibitors 
and need to be optimized.  Several derivations of the ChemBridge compounds have been 
ordered and tested (Figures 60 and 61).  More needs to be done, however to begin to 
develop good SAR. 
 
Resazurin Bioactivity Test 
 The test for bioactivity of any potential inhibitors is important.  It does not do any 
good to develop an excellent enzyme inhibitor that cannot make it across the cell wall to 
reach its target, or is not very specific.  This cell based assay is designed to determine 
whether or not E. coli transformed with a plasmid containing FosA with a leaky promoter 
will be more susceptible to fosfomycin in the presence of increasing concentrations of the 
inhibitors being tested.  In addition, using E. coli transformed with empty vector (plasmid 
without resistance gene) can help determine whether or not the inhibitors being tested 
have any cytotoxic effects on their own.  Other antibiotics, such as kanamycin can be 
used as a positive control. 
 The rate of cell growth for E. coli transformed with FosA begins to decline at 
about 500 µM fosfomycin (Figure 62).  For this reason, this concentration was used in all 
tests of the four ChemBridge compounds from the HTS assay.  At high concentrations, 
around 2-3 mM, there is some decrease in the growth rates for the FosA transformed E. 
coli.  However, it is very probable that this was the result of excess zinc in the 
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compounds, not the compounds themselves, since the same effect was seen in 
transformed cells both with and without FosA. 
 When confirmed hits from the Zn-controlled screen and some of their derivatives 
were screened for their bioactivity, four compounds were found to demonstrate a 
concentration-dependent decrease in the growth rates of E. coli transformed with Pa1129 
FosA (Figure 53).  However, all four of these compounds show similar decreases in the 
growth rates of E. coli without the FosA enzyme indicating some potentially cytotoxic 
activity other than the FosA inhibition (Figure 54).   
 After 24 hours of incubation, however, only three of these compounds show any 
ability to slow the growth of E. coli.  Compound CB 7226895 shows some ability to slow 
initial growth based on the 12 hr. curve, but this ability does not extend to longer time 
points.  The same does not hold true for CB 5155500, CB 6882791, and kk-8-054.  All 
three of these compounds are able to demonstrate long-term decreases in the growth of E. 
coli.  The growth inhibition of E. coli can be monitored visually by noting the lack of 
color change of resazurin in the wells containing high concentrations of these compounds 
in Figure 55.  The growth inhibition can also be monitored spectrofluorometrically with a 
λex = 530 nm and a λex = 590 nm.  Compounds CB 5155500 and CB 6882791 show 
almost no growth for E. coli transformed with Pa1129 FosA above 780 µM of the 
compound.  Interestingly, this same effect is not seen in plates with E. coli transformed 
with an empty pET-20 vector.  The difference in growth rates between E. coli 
transformed with FosA or empty vector pET-20 is a good indication that the lack of 
growth of the cells with FosA is due solely to the inhibition of the FosA enzyme allowing 
the antibiotic fosfomycin to work as it is supposed to and not from a non-specific 
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interaction with other cell enzymes.  There is no difference between transformed cells for 
the compound kk-8-054.  While this compound is the most potent at inhibiting cell 
growth, it does so in cells both with and without FosA.  This is a good indication that the 
ability of this compound to arrest cell growth is not due to its ability to inhibit FosA but 
from some other, non-specific, mechanism. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 60: Structure, ChemBridge ID, and IC50 of four derivatives of hit compounds CB 
5155620 and 5155500. 
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Figure 61: Structure, ChemBridge ID, and IC50 values for four derivatives of hit 
compound CB 6106988 and one derivative of hit compound CB 5847158. 
 
Figure 62: Resazurin growth curves for E. coli transformed with the Pa1129 FosA with 
increasing concentrations of fosfomycin.  Concentrations in the legend are in micromolar. 
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CHAPTER VI 
 
DEVELOPMENT OF A HIGH THROUGHPUT SCREEN FOR THE FOSX ENZYME 
FROM Listeria monocytogenes 
 
Results 
 
Assay with Fluorescent Boronic Acids 
The product of the FosX reaction is a vicinal diol.  Many assays have been 
published using fluorescent boronic acids to detect the vicinal diol of carbohydrates.63,71-
73 Initial experiments with 3-(dansylamino) phenyl boronic acid (DAPBA) in a 
fluorimeter showed no difference in the fluorescence signal with or without the product 
diol.  Several different buffer conditions and concentration ratios of diol to fluorophore 
resulted in similar outcomes. 
 The compound 8-quinoline boronic acid (8-QBA) is reported to give a signal in 
proportion to the concentration of diol product present.63 As such, it should make a good 
fluorophore for testing the FosX reaction.  However, using molar equivalents of 8-QBA 
and purified diol again showed no difference in the fluorescence intensity in reactions 
with and without the diol present.  The lack of sensitivity to the fos-diol product 
concentration indicates that this is not a viable method of assay development (Figure 18). 
 
Adrenaline Based FosX Assay 
 A modified version of the adrenaline assay for the discovery of epoxide 
hydrolases was then developed to try and measure the concentration of the diol product 
indirectly (Figure 19).64,74 As an absorbance based assay rather than a fluorometric one; 
the assay was done in clear 96-well plates.  The reaction works by using sodium 
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periodate to oxidize the diol product formed, with the periodate and substrate/product in 
equal molar concentrations.  Once this reaction is complete adrenaline is added and any 
remaining periodate will oxidize the adrenaline to adrenochrome.  The absorbance of the 
adrenochrome can then be recorded spectrophotometrically.  The more diol product that 
is formed in the enzymatic reaction, the less periodate left over to oxidize the adrenaline 
and the less adrenochrome formed. 
 Phosphonoformate was used as a model inhibitor with the L. monocytogenes 
FosX in the initial stages of developing this assay. Phosphonoformate is not a very good 
inhibitor of the FosX enzymes with an IC50 = ~25 mM.  Also, this assay requires high 
micromolar to low millimolar concentrations of fosfomycin, periodate, and adrenaline.  
Since the compounds screened would only be 10 micromolar, a more sensitive assay was 
deemed necessary. 
 
Gallocyanine Based FosX Assay 
 The assay sensitivity was greatly enhanced with the simple substitution of 
gallocyanine for adrenaline (Figure 20). The oxidation product of gallocyanine by sodium 
periodate is a fluorophore.75 The concentration of fosfomycin used, therefore, is three 
times less with the gallocyanine-based assay and in the same range as that used in the 
FosA assay.  The oxidized form of gallocyanine is able to be detected 
spectrofluorometrically, so black plates are used instead of clear, and sensitivity is greatly 
increased.  The only problem that remained was to find a good model inhibitor for the 
assay.  Again, phosphonoformate is a poor inhibitor of the L. monocytogenes FosX, 
which creates several problems, especially in liquid handling.  In the search for new 
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inhibitors, several other small phosphonates were tested as well as several chelators and 
inactive metals (Figure 63). 
 The other small phosphonates tested were ethylphonsphonic acid (EPA), 
phosphonoacetic acid (PAA), 2-carboxyethylphosphonic acid (CEPA), 
ethyldiethoxyphosphinyl formate, Tris(trimethylsilyl) phosphite, ehtoxycarbonyl 
phosphate (ECP), and acetyl phosphonate.  None of these showed any appreciable 
activity against the L. monocytogenes FosX.  Metal chelators were then tested to see if 
they could inhibit the FosX reaction by either binding to the Mn2+ in the active site or 
pulling the metal out of the enzyme.  The chelators tested were adenosine mono-, di-, and 
triphosphate (AMP, ADP, and ATP), EDTA, EGTA, ADA, citrate, HEDTA, BAPTA, 
and oxalate.  Again, no appreciable activity was seen.  The only thing that worked was 
the last ditch effort of trying inactive metal ions, such as zinc.  In fact, zinc proved to be a 
good inhibitor of the L. monocytogenes FosX with an IC50 = 3.06 ± 0.08 µM. 
 The gallocyanine assay seemed promising for the FosX enzymes; however, when 
DMSO was added to the reaction mixture no inhibition was seen.  By process of 
elimination, it was determined that the DMSO was in fact reacting with the periodate so 
that there was never any remaining to react with the gallocyanine (Figure 64).  The 
reaction of DMSO and periodate resulted in a baseline reaction that made it seem as if no 
inhibition was taking place.  
  
PHOME FosX Assay 
 The compound PHOME can be used in HTS assays for the discovery of inhibitors 
to mammalian soluble epoxide hydrolases.66 There is no similarity in the sequence or 
structure of the mammalian soluble epoxide hydrolases and the L. monocytogenes FosX.
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Figure 63: Flow-chart depicting the search for model inhibitors for the FosX 
gallocyanine-based assay.  Zn2+ finally was chosen and found to have an IC50 = 3 µM. 
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Figure 64: The gallocyanine assay shows a good increase in fluorescence with the 
addition of Zn in the absence of DMSO.  However, the addition of DMSO completely 
diminishes the ability of this assay. 
 
 
 To test the reaction of PHOME with the L. monocytogenes FosX, a series of 
reactions was run using a 2x dilution of PHOME to determine the rate of the reaction 
catalyzed by FosX.  The L. monocytogenes FosX was able to catalyze the reaction, but 
not well.  The calculated kcat = ~4 x 10-4 s-1 with a KM = ~31 mM for a kcat/KM = 13 M-1 s-
1.  This shows that while PHOME is a substrate for the FosX enzyme, it is not a good 
one.  The kcat/KM for the human soluble epoxide hydrolase is on the order of 1 x 105 M-1 
s-1.  This slow of a turnover for the FosX enzyme eliminates this as a viable HTS assay 
(Figure 65). 
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Figure 65: A) The reaction catalyzed by epoxide hydrolase with PHOME.  The 
hydrolyzed product spontaneously decomposes to the fluorescent compound 6-methoxy-
2-napthaldehyde.  B) Michaelis-Menton kinetics for PHOME hydroxylation by the L. 
monocytogenes FosX.  vmax = 0.02529 µM/min, kcat = 0.02529 min-1 = 4.215 x 10-4 s-1.  
KM = 31.45 mM = 3.145 x 10-5 M.  kcat/KM = 13.4 M-1 s-1.  Compare to human sEH: 
kcat/KM = 1.15 x 105 M-1 s-1. 
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Discussion 
 The attempt at developing an HTS assay has now been abandoned since no viable 
assay was ever established.  As a hydrolase enzyme, an assay similar to the FosA assay is 
not feasible since the other substrate is water, a ubiquitous molecule in an aqueous 
environment.  All four of the potential assays tried failed for different reasons, but failed 
nonetheless. 
 The assay using fluorescent boronic acids seemed promising as this type of assay 
has been used for many years in the detection of carbohydrates.  However, most of the 
fluorescent boronic acids on the market are designed for HPLC use, as there is no 
difference in the intensity of fluorescence for the bound and unbound boronic acid.  In 
order for this type of assay to work for HTS there needs to be a strong difference between 
bound and unbound boronic acid to be able to accurately identify the presence of the 
product being formed.  The compound 8-QBA does show a concentration-dependent 
signal with fructose, but did not show a concentration-dependent signal with fos-diol. 
 The periodate based assays seemed more promising, but the reaction of DMSO 
and periodate proved to invalidate the assay.  The adrenaline-based assay required far too 
much substrate for an HTS assay.  Having 1.5 mM fosfomycin as compared to 10 µM of 
the test compounds would immediately eliminate any weak inhibitors and possibly any 
average to moderate ones as well since the compounds would have to really out compete 
fosfomycin to show up in the assay.  Replacing the adrenaline with gallocyanine allows 
for the use of much less fosfomycin, a concentration on par with that used in the FosA 
assay.  Again, this assay works well as long as DMSO is not added.  The FosX enzyme is 
not inhibited very well by phosphonoformate, so a search for a new model inhibitor 
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turned up zinc.  Zinc inhibits the enzyme well, but once DMSO is added, the signal is 
lost.  Even the small amount of DMSO in the reaction, 0.1%, is equivalent to about 18 
mM DMSO – more than enough to react with all of the periodate in the reaction system.   
 One last effort was made to modify an assay used for mammalian soluble epoxide 
hydrolases.  This assay uses the compound PHOME which, when hydroxylated, 
spontaneously decomposes to 6-methoxy-2-napthaldehyde.  The production of the 
napthaldehyde can be measured spectrofluorometrically.  Interestingly, FosX can 
catalyze this reaction despite having no sequence or structural similarity to the 
mammalian soluble epoxide hydrolases.  However, FosX catalyzes the reaction about 
10,000 times less efficiently than the human hydrolase.  With a low efficiency any 
compound inhibiting this reaction wouldn't necessarily be inhibiting the natural reaction 
of the FosX enzymes.  In addition, such a slow reaction rate would lead to many hits of 
very weakly binding inhibitors and leave too many compounds to confirm and recheck.  
This is just not an efficient enough reaction for HTS. 
 No further work was done to develop an assay using the L. monocytogenes FosX. 
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CHAPTER VII 
 
CONCLUSION 
 
 As the rising tide of antibiotic resistant infections continues to inundate clinics 
around the world, the imperative to find solutions becomes more pressing.  One clinically 
valid method of fighting this tide is to make old antibiotics useful again.  The use of 
inhibitors to enzymatically catalyzed antibiotic resistance has been commercially 
successful in combinations of β-lactam antibiotics, such as amoxicillin, and β-lactamase 
inhibitors, like clavulanic acid.  A similar combination of antibiotic and resistance 
inhibitor should be, therefore, a viable tactic to take against other forms of enzymatically 
derived resistance. 
 The antibiotic fosfomycin has been little used over the years despite its broad-
spectrum activity and lack of significant side effects.  In fact, recent analysis has shown 
that fosfomycin alone is able to achieve cure in 80% of infections when used.  Other 
reports have shown that fosfomycin would be a good alternative to more established 
antibiotics, such as linezolid, against Vancomycin Resistant Enterococci (VRE).76  
 The main reason for the lack of fosfomycin use is the amount of resistance that 
has been mounted against it.  Of the five major methods of resistance derived by bacteria 
four have been specifically found in relation to fosfomycin.  Two of these, enzymatic 
degradation and modification, should be able to be counteracted with novel therapeutics.  
It is for this reason that an HTS campaign has been mounted against fosfomycin 
resistance. 
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 For the purposes of the HTS assay the well-studied enzyme FosA from P. 
aeruginosa was used.  The structural and functional elements of this enzyme have been 
largely discerned through crystallographic and computational analysis.  The docking and 
analysis of the GSH binding site helped elucidate this final piece of the puzzle and 
completed the picture of FosA.  The docked structure of GSH in FosA also helped to give 
a keen insight into the possible route of evolution of these very robust inhibition enzymes 
from less robust progenitors.  Still, all of this structural analysis was necessary to better 
understand the rise of antibiotic resistance. 
 Phosphonoformate, an anti-viral compound, is known to inhibit FosA, but its 
antimicrobial activity was not due to specific inhibition of FosA.  Still, the knowledge of 
this inhibition gave a great starting point for developing HTS assays.  After several false 
starts a viable HTS assay has now been established.  The final assay uses Zn as a positive 
control, however, because it is a more potent inhibitor and much cheaper than Pf, 
lowering the overall cost of running a large screen.  Small screens have identified six 
confirmed inhibitors of the FosA enzyme from a mere 4800 compounds to date.  The 
assay works quickly using the purified enzyme and hits were identified at a rate of 0.19% 
and hits were confirmed at a rate of 75%.   
 Subsequent analysis of hits from the compound screens revealed one compound 
whose close structural analogs had IC50 values less than or equal to 1 µM.  In all, seven 
compounds were purchased from ChemBridge and found to be very active at inhibiting 
FosA.  Further testing revealed that the inhibitory activity of these compounds was due to 
a high level of zinc contamination.   
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 Not much work has been done yet on the other confirmed hits because they are 
much weaker inhibitors of FosA.  These compounds may be metal chelators, which are 
often rejected as drug lead compounds, so it will be a challenge to get around this.  Still, 
it is a good start and bodes well for the future discovery of new compounds. 
 An assay to test the bioactivity of these compounds has also been developed.  
This will be important, as the ability of an inhibitor to cross the cell membrane will be 
vital to its success.  Using E. coli transformed with expression plasmids either with or 
without FosA it will be possible to test compounds for their bioactivity and also for their 
specificity.  The combination of bioactivity and specificity will be of utmost importance 
in the development of novel drug compounds. 
 
Future Directions 
 More work will be needed to understand the details of the evolution of robust 
fosfomycin resistance from less robust progenitors.  Future work in this area will focus 
on DNA shuffling of the M. loti FosX to better FosX enzymes and directed evolution of 
the M. loti FosX to make a better FosA.   
 The HTS assay is ready for a larger screen and that will be done in the near future.  
This screen should also work with the FosB enzymes since they also use small thiols.  
This may prove attractive for studies of the S. aereus FosB, for example.  More work will 
also be done to optimize the activity of the inhibitors discovered to date to make them 
more effective, bioactive, and specific. 
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APPENDIX 
NMR DATA FROM CHEMBRIDGE AND KK-5-SERIES OF COMPOUNDS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Figure 66: A) Comparison of the 1H NMR spectra from kk-5-141-2 (same as kk-5-095-
4) in red and CB 5848410 in blue.  B) Comparison of the 1H NMR spectra from kk-5-
141-1 (same as kk-5-095-3) in red and CB 5846450 in blue.  All data shown in this 
appendix was collected at 600 MHz in d6- DMSO.  See Methods for details. 
 
 
A. 
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Figure 67: 1H NMR for CB 5848410 with aromatic region inset. 
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Figure 68: A) COSY spectrum for CB 5848410.  B) HSQC spectrum for CB 5848410.  
C) HMBC spectrum for CB 5848410. 
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Figure 69: A) Selective NOESY experiment targeting interactions with the methyl group 
a δ2.4 ppm showing an interaction with a single proton at δ7.86 ppm (see Figure 75).  B) 
Comparison of the selective NOESY experiment, red, with the full 1H spectrum, blue. 
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Figure 70: 1H NMR for CB 5846450 with aromatic region inset. 
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Figure 71: A) COSY spectrum for CB 5846450.  B) HSQC spectrum for CB 5846450.  
C) HMBC spectrum for CB 5846450. 
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Figure 72: 1H NMR for kk-5-095-1 (equivalent to CB 5838696). 
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Figure 73: A) COSY spectrum for kk-5-095-1.  B) HSQC spectrum for kk-5-095-1.  C) 
HMBC spectrum for kk-5-095-1. 
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Figure 74: 1H NMR of kk-5-095-5 (equivalent to CB 5844324) with aromatic region 
inset. 
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Figure 75: A) COSY spectrum for kk-5-095-5.  B) HSQC spectrum for kk-5-095-5.  C) 
HMBC spectrum for kk-5-095-5. 
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Figure 76: A) Chemical shift data for CB 5848410.  The double-sided arrow labeled 
NOESY indicates the key interaction from the selective NOESY experiment that 
confirmed the stereochemistry of the double bond between the two rings.  B) Chemical 
shift data for CB 5846450. 
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Figure 77: A) Chemical Shift Data for kk-5-095-1 (equivalent to CB 5838696).  B) 
Chemical Shift Data for kk-5-095-5 (equivalent to CB 5844324). 
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